WO2013182580A1

WO2013182580A1 - Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase

Info

Publication number: WO2013182580A1
Application number: PCT/EP2013/061525
Authority: WO
Inventors: Mark Zak; Nancy-Ellen Haynes; Johannes Cornelius Hermann; Kyungjin Kim; Nathan Robert Scott; Lin Yi
Original assignee: F. Hoffmann-La Roche Ag; Hoffmann-La Roche Inc.
Priority date: 2012-06-07
Filing date: 2013-06-05
Publication date: 2013-12-12
Also published as: US8722661B2; EP2858995A1; TW201402576A; BR112014030416A2; MX2014014832A; JP2015522557A; HK1202112A1; CA2873723A1; RU2014151004A; US20130331375A1; KR20150005711A; CN104350056A; AR091271A1

Abstract

There are provided compounds of the formula (I) wherein Q, R₁ and R₂ are defined herein. The compounds have activity as anticancer agents.

Description

P YRROLOP YREVIID ONE AND PYRROLOPYRIDONE INHIBITORS OF

TANKYRASE

CROSS REFERENCE TO PRIOR APPLICATIONS

This application claims the benefit of priority to U.S. 61/656650 filed 06/07/2012 the contents of which is hereby incorporated by reference in its entirety.

FIELD OF THE INVENTION

The present invention relates to pyrrolopyrimidones and pyrrolopyridones which act as inhibitors of tankyrase and are useful in the amelioration or treatment of cancer.

BACKGROUND OF THE INVENTION Cancer is a disease characterized by the loss of appropriate control for cell growth. The

American Cancer Society has estimated that there were in excess of 1.5 million new cases of cancer within the United Stated of America in 2010 and approximately 570,000 deaths that year estimated to be attributable to cancer. The World Health Organization has estimated that cancer was the leading cause of death globally in 2010, with the number of deaths caused by cancer growing to 12 million per year by 2030.

It has been suggested that there are 6 capabilities which need to be developed by cells in order to lead to the formation of cancerous lesions. These traits are self-sufficiency in growth signals, insensitivity to anti-growth signals, tissue invasion and metastasis, limitless replication potential, sustained angiogenesis and evasion of apoptosis. Growth signaling is required for cells to transition from a quiescent state into an active proliferative state. These signals are typically transmitted from transmembrane receptors, through signal transduction cascades involving numerous intracellular kinases, eventually resulting in changes in gene expression at the nuclear level within the cell. In recent years there has been much interest in the area of signal transduction inhibitors, particularly kinase inhibitors, and their use for the treatment of cancer. Several examples from this class of compounds have been successfully evaluated in clinical settings and are now commercially available and marketed for the treatment of specific forms of cancer e.g. imatinib tosylate (marketed as Gleevec® by Novartis for the treatment of Philadelphia chromosome -positive chronic myeloid leukemia), lapatinib ditosylate (marketed as Tykerb® by Glaxo SmithKline for the treatment of HER2 positive breast cancer in combination with other chemotherapeutic agents), sunitinib malate (marketed as Sutent® by Pfizer and approved for the treatment of renal cancer) and sorafenib (marketed as Nexavar by Bayer for the treatment of renal cancer).

In addition to the growth factor associated signaling pathways, which predominantly utilize kinase catalyzed transfer of phosphate groups as the key component of the signaling pathway, numerous other signaling pathways also exist within cells and their proper regulation is critical for maintaining correct levels of cell growth and replication. In the emerging area of cancer stem cell inhibition the Wnt, Notch and Hedgehog pathways have received much interest as potential ways in which to avoid tumor relapse and metastasis. The Wnt pathway is instrumental in embryonic development and in tissue maintenance in adults with the activity of individual components within the pathway under tight regulation. In cancer and other diseases cell signaling pathways no longer exhibit the appropriate level of control. In the case of the Wnt pathway, signal transduction is controlled by the relative stabilities of 2 proteins, axin and β- catenin. An overabundance of β-catenin leads to increased Wnt signaling and activation of associated nuclear transcription factors while excess axin results in the degradation of intracellular β-catenin and decreased signaling. Dysregulation of the canonical Wnt signaling pathway has been implicated in a range of human carcinomas such as colon cancer, hepatocellular carcinoma, endometrial ovarian cancer, pilomatricoma skin cancer, prostate cancer, melanoma and Wilms tumor.

In the canonical Wnt signaling pathway signaling is initiated by interaction of a Wnt ligand with a receptor complex containing a Frizzled family member and low-density lipoprotein receptor-related protein. This leads to the formation of a disheveled-frizzled complex and relocation of axin from the destruction complex to the cell membrane. Axin is the concentration limiting component of the destruction complex, and it is this complex which is formed with adenomatous polyposis coli proteins, casein-kinase la and glycogen synthase kinase 3β which is responsible for controlling intracellular levels of β-catenin. In the presence of functional destruction complex, β-catenin is sequentially phosphorylated by casein-kinase la and glycogen synthase kinase 3β on a conserved set of serine and threonine residues at the amino-terminus. Phosphorylation facilitates binding of β-catenin to β-transducin repeat-containing protein which then mediates ubiquitination and subsequent proteasomal degradation of β-catenin. In the absence of sufficiently elevated concentrations of the destruction complex, un-phosphorylated β- catenin is able to migrate to the cell nucleus and interact with T-cell factor proteins and convert them into potent transcriptional activators through the recruitment of co-activator proteins.

It has recently been reported that intracellular axin levels are influenced by the poly(ADP-ribose) polymerase enzyme family members tankyrase-1 and tankyrase-2 (also known as PARP5a and PARP5b) (Nature Chemical Biology 2009, 5, 100 and Nature 2009, 461, 614). Tankyrase enzymes are able to poly-ADP ribosylate (PARsylate) axin, which marks this protein for subsequent ubiquitination and proteasomal degradation. Thus, it would be expected that in the presence of an inhibitor of tankyrase catalytic activity, axin protein concentration would be increased, resulting in higher concentration of the destruction complex and decreased concentrations of unphosphorylated intracellular β-catenin and decreased Wnt signaling. An inhibitor of tankyrase- 1 and -2 would also be expected to have an effect on other biological functions of the tankyrase proteins e.g. chromosome end protection (telomeres), insulin responsiveness and spindle assembly during mitosis (Biochimie 2009, 5, 100).

Therapeutics which are directed at and can correct dysregulation of the Wnt signaling pathway have been implicated in conditions such as bone density defects, coronary disease, late onset Alzheimer's disease, familial exudative vitreoretinopathy, retinal angiogenesis, tetra- amelia, Mullerian-duct regression and virilization, SERKAL syndrome, type 2 diabetes, Fuhrmann syndrome, skeletal dysplasia, focal dermal hypoplasia and neural tube defects. Although the above introduction has focused on the relevance of Wnt signaling in cancer, the Wnt signaling pathway is of fundamental importance and has potential implication in a broad range of human diseases, not necessarily limited to the examples provided above for illustrative purposes.

SUMMARY OF THE INVENTION There is a continuing need for new and novel therapeutic agents that can be used for cancer and hyperproliferative conditions. The tankyrase enzymes, which modulate Wnt activity, are members of the PARP family. Design and development of new pharmaceutical compounds that inhibit or modulate their activity is essential. In one aspect of the present invention there is provided a compound according to formula I

wherein:

Q and X are independently in each occurrence N or CH; Ri is selected from the group consisting of hydrogen, Ci_6 alkyl, Ci_6 alkenyl, Ci_6 hydroxyalkyl, Ci_6-dihydroxyalkyl, C3-7 cycloalkyl;

Y is selected from the group consisting of CR⁴R⁵, NR⁴ or -O- wherein R⁵ is hydrogen, Ci-6 alkyl;

Rt is Ci-6 alkyl, Ci_6 alkylsulfonyl, Ci_6 acyl, phenyl or heteroaryl said heteroaryl selected from pyridinyl, pyrazinyl or pyrimidinyl and said phenyl and said heteroaryl optionally substituted by one to three substituents independently selected from the group consisting of halogen, CN, Ci_6 alkylsulfonyl, Ci_6 haloalkyl, Ci_6 hydroxyalkyl, C₁-3 alkoxy- C₁-3 alkyl, Ci_6 alkoxycarbonyl, carboxy, CONRt_bR_4C wherein R_4b and Rt_c are independently in each occurrence hydrogen or C₁-3 alkyl and ORt_a wherein Rt_a is selected from the group consisting of (i) hydrogen, (ii) Ci_6 alkyl, (iii) C₁-3 alkoxy-Ci-3 alkyl, (iv) Ci_6 hydroxyalkyl and (v) Ci_6 dihydroxyalkyl;

R6 is halogen or hydrogen, R3 is selected from the group consisting of hydrogen, Ci-₆ alkyl, substituted alkyl, Ci-₆ haloalkyl, Ci-₆ hydroxyalkyl, Ci-₆ dihydroxyalky 1, C1-3 alkoxy- C1-3 alkyl, halogen, CN, trifiuoromethyl, Ci-₆ alkoxycarbonyl, Ci-₆ alkylsulfonyl, CONRtbRtc wherein Rt_b and Rt_c are independently in each occurrence hydrogen or C₁-3 alkyl, and OR_3a wherein R_3a is selected from the group consisting of (i) hydrogen, (ii) Ci-₆ alkyl, (iii) C1-3 alkoxy-Ci-3 alkyl, (iv) Ci-₆ hydroxyalkyl and (v) Ci-₆ dihydroxyalkyl; or, a pharmaceutically acceptable salt thereof.

There are provided compounds of the formula

or a pharmaceutically acceptable salt thereof, wherein A, Q, Ri and R₂ are as defined below. The present invention additionally relates to pharmaceutical compositions comprising one or more compounds of the invention, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier or excipient.

The present invention further relates to a method of treating, ameliorating or preventing cancer in a mammal, preferably a human, comprising administering to said mammal a therapeutically effective amount of a compound according to the invention or a pharmaceutically acceptable salt thereof.

DETAILED DESCRIPTION OF THE INVENTION

The phrase "a" or "an" entity as used herein refers to one or more of that entity; for example, a compound refers to one or more compounds or at least one compound. As such, the terms "a" (or "an"), "one or more", and "at least one" can be used interchangeably herein.

The phrase "as defined herein above" refers to the broadest definition for each group as provided in the Summary of the Invention or the broadest claim. In all other embodiments provided below, substituents which can be present in each embodiment and which are not explicitly defined retain the broadest definition provided in the Summary of the Invention.

As used in this specification, whether in a transitional phrase or in the body of the claim, the terms "comprise(s)" and "comprising" are to be interpreted as having an open-ended meaning. That is, the terms are to be interpreted synonymously with the phrases "having at least" or "including at least". When used in the context of a process, the term "comprising" means that the process includes at least the recited steps, but may include additional steps. When used in the context of a compound or composition, the term "comprising" means that the compound or composition includes at least the recited features or components, but may also include additional features or components.

The term "independently" is used herein to indicate that a variable is applied in any one instance without regard to the presence or absence of a variable having that same or a different definition within the same compound. Thus, in a compound in which R" appears twice and is defined as "independently carbon or nitrogen", both R"s can be carbon, both R"s can be nitrogen, or one R" can be carbon and the other nitrogen.

When any variable (e.g., R¹, R^4a, Ar, X¹ or Het) occurs more than one time in any moiety or formula depicting and describing compounds employed or claimed in the present invention, its definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such compounds result in stable compounds.

A " drawn through a bond indicates the point of attachment of a functional group or other chemical moiety to the rest of the molecule of which it is a part. Thus, for example:

MeC(=0)OR⁴ wherein R⁴ is—-<] ^ MeC(=0)0— <]

A bond drawn into ring system (as opposed to connected at a distinct vertex) indicates that the bond may be attached to any of the suitable ring atoms.

The term "optional" or "optionally" as used herein means that a subsequently described event or circumstance may, but need not, occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example, "optionally substituted" means that the optionally substituted moiety may incorporate a hydrogen or a substituent.

The term "about" is used herein to mean approximately, in the region of, roughly, or around. When the term "about" is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values set forth. In general, the term "about" is used herein to modify a numerical value above and below the stated value by a variance of 20%.

As used herein, the recitation of a numerical range for a variable is intended to convey that the invention may be practiced with the variable equal to any of the values within that range. Thus, for a variable which is inherently discrete, the variable can be equal to any integer value of the numerical range, including the end-points of the range. Similarly, for a variable which is inherently continuous, the variable can be equal to any real value of the numerical range, including the end-points of the range. As an example, a variable which is described as having values between 0 and 2, can be 0, 1 or 2 for variables which are inherently discrete, and can be 0.0, 0.1, 0.01, 0.001, or any other real value for variables which are inherently continuous.

In one embodiment of the present invention there is provided a compound according to formula la:

wherein Q is N or CH; A is CH ,Ri is selected from the group consisting of hydrogen, alkyl, cycloalkyl, hydroxyalkyl, dihydroxyalkyl and alkenyl, R₂ is

R4 is alkyl, alkylsulfonyl, alkyl ketone or

X is CH or N; Y is selected from the group consisting of nitrogen, oxygen or carbon; R₅ is halogen, CN, alkylsulfonyl or haloalkyl; R₆ is halogen or hydrogen, R₃ and R₇ is selected from the group consisting of hydrogen, alkyl, substituted alkyl, haloalkyl, halogen, O-alkyl, O- substituted alkyl, CN, trifiuoromethyl, carboxyalkyl, alkylsulfonyl and carboxamide; and n is 0 to 3; or a pharmaceutically acceptable salt thereof.

In another embodiment of the present invention there is provided a compound according to formula I wherein Ri is selected from hydrogen or alkyl, R₂ is:

R4 is phenyl or heteroaryl said heteroaryl selected from pyridinyl, pyrazinyl or pyrimidinyl and said phenyl and said heteroaryl optionally substituted by one to three substituents independently selected from the group consisting of halogen, CN, Ci_6 alkylsulfonyl, Ci-6 haloalkyl, Ci_6 hydroxyalkyl, Ci_₃ alkoxy- Ci_₃ alkyl, Ci_6 alkoxycarbonyl, carboxy, CONR_4bR_4c wherein R^, and Rt_c are independently in each occurrence hydrogen or Ci_₃ alkyl and OR_4a wherein R_4a is selected from the group consisting of (i) Ci_6 alkyl, (ii) C_1-3 alkoxy-Ci_₃ alkyl, (iii) Ci_₆ hydroxyalkyl and (iv) Ci_₆ dihydroxyalkyl;

In another embodiment of the present invention there is provided a compound of the formula (I)

wherein

Q and X are independently in each occurrence N or CH;

R¹ is selected from the group consisting of hydrogen, Ci_6 alkyl, Ci_6 alkenyl, Ci_6 hydroxyalkyl, Ci-6-dihydroxyalkyl, C₃_₇ cycloalkyl;

diazabicyclo [2.2.1 ]heptanyl;

Y is selected from the group consisting of CR⁴R⁵, NR⁴ or -O- wherein R⁵ is hydrogen, Ci_6 alkyl;

Rt is Ci-6 alkyl, Ci_6 alkylsulfonyl, Ci_6 acyl, phenyl or heteroaryl said heteroaryl selected from, pyridinyl, pyrazinyl or pyrimidinyl and said phenyl and said heteroaryl optionally substituted by one to three substituents independently selected from the group consisting of halogen, CN, Ci_6 alkylsulfonyl, Ci_6 haloalkyl, Ci_6 hydroxyalkyl, Ci_₃ alkoxy- Ci_₃ alkyl, Ci_6 alkoxycarbonyl, carboxy, CONRt_bR_4C wherein R_4b and Rt_c are independently in each occurrence hydrogen or Ci_₃ alkyl and ORt_a wherein Rt_a is selected from the group consisting of (i) hydrogen, (ii) Ci_6 alkyl, (iii) Ci_₃ alkoxy, (iv) Ci_₃ alkoxy-Ci_₃ alkyl, (v) Ci_6 hydroxyalkyl and (vi) Ci-6 dihydroxyalkyl;

R₃ is selected from the group consisting of hydrogen, Ci_6 alkyl, Ci_6 alkoxy, substituted alkyl, Ci_6 haloalkyl, Ci_6 hydroxyalkyl, Ci_6 dihydroxyalky 1, Ci_₃ alkoxy-Ci_₃ alkyl, halogen, CN, trifluoromethyl, Ci_6 alkoxycarbonyl, Ci_6 alkylsulfonyl, CONR_4bR_4c wherein Rt_b and Rt_c are independently in each occurrence hydrogen or Ci_₃ alkyl, and OR_3a wherein R_3a is selected from the group consisting of (i) hydrogen, (ii) Ci_6 alkyl, (iii) C_1-3 alkoxy-Ci_₃ alkyl, (iv) Ci_6 hydroxyalkyl and (v) Ci_6 dihydroxyalkyl; or, a pharmaceutically acceptable salt thereof.

In another embodiment of the present invention there is provided a compound of formula

(I)

wherein

Q and X are independently in each occurrence N or CH;

Rt is Ci-6 alkyl, Ci_6 alkylsulfonyl, Ci_6 acyl, phenyl or heteroaryl said heteroaryl selected from, pyridinyl, pyrazinyl or pyrimidinyl and said phenyl and said heteroaryl optionally substituted by one to three substituents independently selected from the group consisting of halogen, CN, Ci_6 alkylsulfonyl, Ci_6 haloalkyl, Ci_6 hydroxyalkyl, Ci_₃ alkoxy- Ci_₃ alkyl, Ci_6 alkoxycarbonyl, carboxy, CONRt_bR_4C wherein R_4b and Rt_c are independently in each occurrence hydrogen or Ci_₃ alkyl and ORt_a wherein Rt_a is selected from the group consisting of (i) hydrogen, (ii) Ci_6 alkyl, (iii) Ci_₃ alkoxy-Ci_₃ alkyl, (iv) Ci_6 hydroxyalkyl and (v) Ci_6 dihydroxyalkyl;

R₆ is halogen or hydrogen;

R₃ is selected from the group consisting of hydrogen, Ci_6 alkyl, substituted alkyl, Ci_6 haloalkyl, Ci_6 hydroxyalkyl, Ci_6 dihydroxyalky 1, Ci_₃ alkoxy-Ci_₃ alkyl, halogen, CN, trifiuoromethyl, Ci_6 alkoxycarbonyl, Ci_6 alkylsulfonyl, CONRt_bRt_c wherein Rt_b and Rt_c are independently in each occurrence hydrogen or C_1-3 alkyl, and OR_3a wherein R_3a is selected from the group consisting of (i) hydrogen, (ii) Ci_6 alkyl, (iii) C_1-3 alkoxy-Ci_₃ alkyl, (iv) Ci_6 hydroxyalkyl and (v) Ci_6 dihydroxyalkyl; or, a pharmaceutically acceptable salt thereof.

In another embodiment of the present invention there is provided a compound of formula I, wherein:

Q and X are independently in each occurrence N or CH;

diazabicyclo[2.2.1]heptanyl;

Rt is Ci-6 alkyl, Ci_6 alkylsulfonyl, Ci_6 acyl, phenyl or heteroaryl said heteroaryl selected from, pyridinyl, pyrazinyl or pyrimidinyl and said phenyl and said heteroaryl optionally substituted by one to three substituents independently selected from the group consisting of halogen, CN, Ci_6 alkylsulfonyl, Ci_6 haloalkyl, Ci_6 alkoxycarbonyl, carboxy, CONRt_bR4c wherein Rt_b and Rt_c are independently in each occurrence hydrogen or C_1-3 alkyl and ORt_a wherein Rt_a is C_1-3 alkoxy;

R₃ is selected from the group consisting of hydrogen, Ci_6 alkyl, Ci_6 alkoxy, Ci_6 haloalkyl, and CN; or, a pharmaceutically acceptable salt thereof.

Ri is selected from hydrogen or alkyl,

R₄ is phenyl or heteroaryl said heteroaryl selected from pyridinyl, pyrazinyl or pyrimidinyl and said phenyl and said heteroaryl optionally substituted by one to three substituents independently selected from the group consisting of halogen, CN, Ci_6 alkylsulfonyl, Ci-6 haloalkyl, Ci_6 hydroxyalkyl, C₁-3 alkoxy- C₁-3 alkyl, Ci_6 alkoxycarbonyl, carboxy, CONR_4bR_4c wherein Rt_b and Rt_c are independently in each occurrence hydrogen or C₁-3 alkyl and ORt_a wherein Ri_a is selected from the group consisting of (i) Ci_6 alkyl, (ii) C₁-3 alkoxy-Ci-3 alkyl, (iii) Ci_6 hydroxyalkyl and (iv) Ci_₆ dihydroxyalkyl.

In another embodiment of the present invention there is provided a compound of formula I, wherein Q is N. In another embodiment of the present invention there is provided a compound of formula

I, wherein Q is CH.

In another embodiment of the present invention there is provided a compound of formula I, wherein Ri is Ci_6 alkyl.

In another embodiment of the present invention there is provided a compound of formula I, wherein Ri is methyl.

In another embodiment of the present invention there is provided a compound of formula I, wherein Ri is hydrogen.

In another embodiment of the present invention there is provided a compound of formula I, wherein Ri is Ci_6 alkenyl. In another embodiment of the present invention there is provided a compound of formula

I, wherein Ri is Ci_6 hydroxyalkyl.

In another embodiment of the present invention there is provided a compound of formula I, wherein Ri is Ci-6-dihydroxyalkyl.

In another embodiment of the present invention there is provided a compound of formula I, wherein Ri is C3-7 cycloalkyl.

In another embodiment of the present invention there is provided a compound of formula I, wherein R₂ is 2,5-diazabicyclo[2.2.1]heptanyl; In another embodiment of the present invention there is provided a compound of formula

I, wherein R₂

-N Y

I, wherein R₂ is

I, wherein R₂

In another embodiment of the present invention there is provided a compound of formula I, wherein one X is N and the other one is CH.

In another embodiment of the present invention there is provided a compound of formula I, wherein both X are CH.

In another embodiment of the present invention there is provided a compound of formula I, wherein R₃ is halogen-C_h alky!. In another embodiment of the present invention there is provided a compound of formula

I, wherein R₃ is F₃C-.

In another embodiment of the present invention there is provided a compound of formula I, wherein R₃ is Ci_6 alkoxy.

In another embodiment of the present invention there is provided a compound of formula I, wherein R₃ is ethoxy.

In another embodiment of the present invention there is provided a compound of formula I, wherein R₃ is methoxy. In another embodiment of the present invention there is provided a compound of formula I, wherein R₃ is hydrogen.

In another embodiment of the present invention there is provided a compound of formula I, wherein R₃ is cyano. In another embodiment of the present invention there is provided a compound of formula

I, wherein R₃ is Ci_6 alkyl.

In another embodiment of the present invention there is provided a compound of formula I, wherein R₃ is methyl.

I, wherein R₂

I, wherein R₂

In another embodiment of the present invention there is provided a compound of formula I, wherein Y is NR4. In another embodiment of the present invention there is provided a compound of formula

I, wherein R4 is phenyl, optionally substituted by cyano, halogen, halogen-Ci-6 alkyl, or Ci_6 alkyl-0₂S-.

In another embodiment of the present invention there is provided a compound of formula I, wherein R4 is phenyl. In another embodiment of the present invention there is provided a compound of formula

I, wherein R, is CH₃-CH₂-0-(C=0)-phenyl.

In another embodiment of the present invention there is provided a compound of formula I, wherein R4 is phenyl substituted by halogen.

In another embodiment of the present invention there is provided a compound of formula I, wherein R4 is phenyl substituted by chloro. In another embodiment of the present invention there is provided a compound of formula I, wherein R4 is phenyl substituted by fiuoro.

In another embodiment of the present invention there is provided a compound of formula I, wherein R4 is phenyl substituted by bromo. In another embodiment of the present invention there is provided a compound of formula

I, wherein R4 is phenyl substituted by cyano.

In another embodiment of the present invention there is provided a compound of formula I, wherein R4 is phenyl substituted by halogen and Ci_6 alkyl-0₂S-.

In another embodiment of the present invention there is provided a compound of formula I, wherein R4 is 4-fluoro-2-(methylsulfonyl)phenyl.

In another embodiment of the present invention there is provided a compound of formula I, wherein R4 is CH₃-CH₂-NH-(C=0)-phenyl.

In another embodiment of the present invention there is provided a compound of formula I, wherein R4 is phenyl substituted by difiuoro and methoxy-ethoxy. In another embodiment of the present invention there is provided a compound of formula

I, wherein R4 is pyridinyl, optionally substituted by halogen or halogen-Ci-6 alkyl.

In another embodiment of the present invention there is provided a compound of formula I, wherein R4 is pyridinyl.

In another embodiment of the present invention there is provided a compound of formula I, wherein R4 is pyridinyl substituted by halogen.

In another embodiment of the present invention there is provided a compound of formula I, wherein R4 is pyridinyl substituted by fluoro.

In another embodiment of the present invention there is provided a compound of formula I, wherein R4 is pyridinyl substituted by chloro. In another embodiment of the present invention there is provided a compound of formula

I, wherein R4 is pyridinyl substituted by cyano. In another embodiment of the present invention there is provided a compound of formula I, wherein R4 is pyridinyl substituted by halogen-Ci-6 alkyl.

In another embodiment of the present invention there is provided a compound of formula I, wherein R4 is pyridinyl substituted by F₃C-. In another embodiment of the present invention there is provided a compound of formula

I, wherein R4 is piperazinyl.

In another embodiment of the present invention there is provided a compound of formula I, wherein R4 is acetyl.

In another embodiment of the present invention there is provided a compound of formula I, wherein R4 is methylsulfonyl.

In another embodiment of the present invention there is provided a compound of formula I, wherein R4 is Ci_₆alkyl.

In another embodiment of the present invention there is provided a compound of formula I, wherein R4 is methyl. In another embodiment of the present invention there is provided a compound of formula

I, wherein R4 is pyrimidyl.

In another embodiment of the present invention there is provided a compound of formula I, selected from the group consisting of:

7-Methyl-2-(4^yridin-4-yl-piperazin-l-yl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one, 4-[4-(7-Methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)-piperazin-l-yl]- benzoic acid ethyl ester,

2-[4-(4-Chloro-phenyl)-piperazin-l-yl]-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4- one,

7-Methyl-2-(4^yridin-2-yl-piperazin-l-yl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one, 2-[4-(4-Fluoro-2-methanesulfonyl-phenyl)-piperazin-l-yl]-7-methyl-3,7-dihydro- pyrrolo[2,3-d]pyrimidin-4-one, 7-Methyl-2-[4-(3-trifluoromethyl-pyridm^

d]pyrimidin-4 -one ,

2-[4-(3,5-Dichloro-phenyl)-piperazin-l-yl]-7-methyl-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4 -one , 7-Methyl-2-(4-pyrimidin-2-yl-piperazin-l-yl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4- one,

2-[4-(7-Methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)-piperazin-l-yl]- nicotinonitrile,

4-(7-Methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)-3,4,5,6-tetrahydro-2H- [1 ,2']bipyrazinyl-3'-carbonitrile,and,

7-Methyl-2-(4-methyl-piperazin-l-yl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one.

In another embodiment of the present invention there is provided a compound of formula I, selected from the group consisting of

7-Με^1-2^ο ^1ίη-4^1-3,7-ά^άΓθ-ρ}ττο1ο[2,3-ά]ρ}τ^ίάίη-4-οη6, 2-(4-Methanesulfonyl-piperazin-l-yl)-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4- one,

2-(4-Acetyl-piperazin-l-yl)-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one,

2- [3 -(4-Bromo-phenyl)-3 -methyl-azetidin- 1 -yl] -7 -methyl-3 ,7-dihydro-pyrrolo [2 ,3 - d]pyrimidin-4 -one , 7-Methyl-2-(3-phenyl-pyrrolidin-l-yl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one,

2-[4-(4-Fluoro-phenyl)-piperazin-l-yl]-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4- one,

2-[4-(3-Fluoro-phenyl)-piperazin-l-yl]-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4- one, 2-[4-(7-Methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)-piperazin-l-yl]- benzonitrile, 2- [4-(2,4-Difluoro-phenyl)-piperazin-l-yl]-7-methyl-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4 -one ,

3- [4-(7-Methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)-piperazin-l-yl]- benzonitrile, and, 4-[4-(7-Methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)-piperazin-l-yl]- benzonitrile.

7-Methyl-2-[4-(2-trifluoromethyl-phenyl)-piperazin-l-yl]-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4-one,

2-[4-(2-Fluoro-4-methanesulfonyl-phenyl)-piperazin-l-yl]-7-methyl-3,7-dihydro- pyrrolo[2,3-d]pyrimidin-4-one,

7-Methyl-2-[4-(4-trifluoromethyl-pyridin-2-yl)-piperazin-l-yl]-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4 -one , 2-[4-(3 ,4-Dichloro-phenyl)-piperazin- 1 -yl]-7-methyl-3 ,7-dihydro-pyrrolo [2 ,3 - d]pyrimidin-4 -one ,

7-But-3-enyl-2-[4-(2-chloro-phenyl)-piperazin-l-yl]-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4 -one ,

2-[4-(2-Fluoro-phenyl)-piperazin-l-yl]-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4- one,

7-Methyl-2-(4-phenyl-piperazin-l-yl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one, 2-[4-(2-Chloro-phenyl)-piperazin-l-yl]-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4- one,

7-Methyl-2-(2,3,5,6-tetrahydro-[l,2']bipyrazinyl-4-yl)-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4-one,

6-[4-(7-Methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)-piperazin-l-yl]- nicotinonitrile, 2-[(lS,4S)-5-(3-Fluoro-phenyl)-2,5-diaza-bicyclo[2.2.1]hept-2-yl]-7-methyl-3,7-dihydro- pyrrolo[2,3-d]pyrimidin-4-one and

2-[4-(3,5-Dichloro-pyridin-4-yl)-piperazin-l-yl]-7-methyl-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4-one.

6- [4-(2-Fluoro-phenyl)-piperazin-l -yl]- 1 -methyl- 1 ,5-dihydro-pyrrolo[3,2-c]pyridin-4- one,

1 -Ethyl-6-[4-(2-fluoro-phenyl)-piperazin- 1 -yl]- 1 ,5-dihydro-pyrrolo[3,2-c]pyridin-4-one, 2-(4-Trifiuoromethyl-phenyl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one,

7- Methyl-2-(4-trifluoromethyl-phenyl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one, 2-(4-Methoxy-phenyl)-7-methyl-3 ,7-dihydro-pyrrolo [2 ,3 -d]pyrimidin-4-one, 2-(6-Ethoxy-pyridin-3-yl)-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one, 7-Methyl-2-pyridin-3-yl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one, 7-Methyl-2-(6-methyl-pyridin-3-yl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one, 4-(7-Methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)-benzonitrile, 7-Methyl-2-(6-trifluoromethyl-pyridin-3-yl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one, l-Methyl-6-(4-trifluoromethyl-phenyl)-l,5-dihydro-pyrrolo[3,2-c]pyridin-4-one,

1- Ethyl-6-(4-trifiuoromethyl-phenyl)-l,5-dihydro-pyrrolo[3,2-c]pyridin-4-one and

1 -Methyl-6-(l -methyl- lH-pyrazol-4-yl)- 1 ,5 -dihydro-pyrrolo [3 ,2-c]pyridin-4-one .

2- [4-(4-Fluoro-phenyl)-piperidin-l-yl]-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4- one, 7-But-3-enyl-2-(4 rifluoromethyl^henyl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one,

7-Ethyl-2-(4 rifluoromethyl^henyl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one,

7-Propyl-2-(4^rifluoromethyl-phenyl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one,

7-Allyl-2-(4^rifluoromethyl^henyl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one, 7-(3,4-Dihydroxy-butyl)-2-(4-trifluoromethyl-phenyl)-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4 -one ,

7-(2,3-Dihydroxy-propyl)-2-(4-trifluoromethyl-phenyl)-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4 -one ,

N-Ethyl-4-[4-(7-methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)-piperazin- l-yl]-benzamide,

7-Methyl-2-pyrazol- 1 -yl-3 ,7-dihydro-pyrrolo[2 ,3 -d]pyrimidin-4-one,

7-Hydroxymethyl-2-(4-trifluoromethyl-phenyl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4- one,

7-Methyl-2-(3-methyl-3-phenyl-azetidin-l-yl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4- one,

7-Cyclopropyl-2-(4-trifluoromethyl-phenyl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one,

2-[4-(2-Fluoro-phenyl)-piperazin-l-yl]-7-hydroxymethyl-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4 -one ,

2-[4-(2,6-Difluoro-phenyl)-piperazin-l-yl]-7-(2,3-dihydroxy-propyl)-3,7-dihydro- pyrrolo[2,3-d]pyrimidin-4-one, and,

7-Methyl-2-phenyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one.

In another embodiment of the present invention there is provided a compound of formula I, which compound is 2-[4-[2 6-difluoro-4-(2-methoxyethoxy)phenyl]piperazin-l-yl]-7-(2- hydroxyethyl)-3H-pyrrolo[2 3-d]pyrimidin-4-one. In another embodiment of the present invention there is provided a compound of formula

I as described herein for use as therapeutically active substance. In another embodiment of the present invention there is provided a method of inhibiting tankyrase 1 and/or tankyrase 2 by contacting either or both with a compound as described herein.

In another embodiment of the present invention there is provided a method for treating cancer by administering to a patient in need thereof a therapeutically active amount of a compound as described herein.

In another embodiment of the present invention there is provided a method for treating colorectal cancer by administering to a patient in need thereof a therapeutically active amount of a compound as described herein.

In another embodiment of the present invention there is provided a use of a compound as described herein for the preparation of a medicament for the treatment of cancer, in particular colorectal cancer.

In another embodiment of the present invention there is provided a use of a compound as described herein for the preparation of a medicament for the treatment of colorectal cancer.

In another embodiment of the present invention there is provided a compound of formula (I) as described herein for the use as therapeutically active substance for the therapeutic and/or prophylactic treatment of cancer, in particular colorectal cancer.

In another embodiment of the present invention there is provided a compound of formula (I) as described herein for the use as therapeutically active substance for the therapeutic and/or prophylactic treatment of colorectal cancer.

In another embodiment of the present invention there is provided a composition containing a compound as described herein and at least one pharmaceutically acceptable carrier, diluent or excipient.

In another embodiment of the present invention there is provided a compound according to formula I which compound is:

7-Methyl-2-(4^yridin-4-yl-piperazin-l-yl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one,

4-[4-(7-Methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)-piperazin-l-yl]- benzoic acid ethyl ester, 2-[4-(4-Chloro-phenyl)^iperazin-l-yl]-7-m

one,

7-Methyl-2-(4-pyridin-2-yl-piperazin-l-yl)-3,7-d^

2-[4-(4-Fluoro-2-methanesulfonyl-phenyl)-piperazin-l-yl]-7-methyl-3,7-dihydro- pyrrolo[2,3-d]pyrimidin-4-one,

7-Methyl-2-[4-(3-trifluoromethyl^yridin-2-yl)^iperazin-l-yl]-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4 -one ,

4-(7-Methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)-3,4,5,6-tetrahydro-2H- [1 ,2']bipyrazinyl-3'-carbonitrile,

7-Methyl-2-(4-methyl-piperazin- 1 -yl)-3 ,7-dihydro-pyrrolo [2 ,3 -d]pyrimidin-4-one,

7-Με^1-2-ηιο 1ιο1ίη-4^1-3,7-ά^άΓθ-ρ}ττο1ο[2,3-ά]ρ}τίηιίάίη-4-οη6,

2-(4-Methanesulfonyl-piperazin-l-yl)-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4- one, 2-(4-Acetyl-piperazin-l-yl)-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one,

2- [3 -(4-Bromo-phenyl)-3 -methyl-azetidin- 1 -yl] -7 -methyl-3 ,7-dihydro-pyrrolo [2 ,3 - d]pyrimidin-4 -one ,

7-Methyl-2-(3-phenyl-pyrrolidin-l-yl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one, 2-[4-(4-Fluoro-phenyl)-piperazin-l-yl]-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4- one, 2-[4-(3-Fluoro-phenyl)^iperazin -yl]-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4- one,

2- [4-(7-Methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)-piperazin-l-yl]- benzonitrile, 2-[4-(2,4-Difluoro-phenyl)-piperazin-l-yl]-7-methyl-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4-one,

3- [4-(7-Methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)-piperazin-l-yl]- benzonitrile,

4- [4-(7-Methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)-piperazin-l-yl]- benzonitrile,

2-[4-(2-Fluoro-4-methanesulfonyl-phenyl)-piperazin-l -yl]-7-methyl-3,7-dihydro- pyrrolo[2,3-d]pyrimidin-4-one, 7-Methyl-2-[4-(4^rifluoromethyl^yridin-2-yl)^iperazin-l-yl]-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4-one,

2-[4-(3,4-Dichloro-phenyl)-piperazin-l-yl]-7-methyl-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4-one,

7-But-3-enyl-2-[4-(2-chloro-phenyl)-piperazin-l-yl]-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4-one,

2-[4-(2-Fluoro-phenyl)-piperazin -yl]-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4- one,

7-Methyl-2-(4-phenyl-piperazin-l -yl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one, 2-[4-(2-Chloro-phenyl)^iperazin-l-yl]-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4- one,

7-Methyl-2-(2,3,5,6-tetrahydro-[l,2']bipyrazinyl-4-yl)-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4-one, 6-[4-(7-Methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)-piperazin-l-yl]- nicotinonitrile,

2-[(lS,4S)-5-(3-Fluoro-phenyl)-2,5-diaza-bicyclo[2.2.1]hept-2-yl]-7-methyl-3,7-dihydro- pyrrolo[2,3-d]pyrimidin-4-one,

2-[4-(3,5-Dichloro-pyridin-4-yl)-piperazin-l-yl]-7-methyl-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4 -one ,

1 -Ethyl-6-[4-(2-fluoro-phenyl)-piperazin- 1 -yl]- 1 ,5-dihydro-pyrrolo[3,2-c]pyridin-4-one, 2-(4-Trifluoromethyl-phenyl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one,

7- Methyl-2-(4-trifluoromethyl-phenyl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one, 2-(4-Methoxy-phenyl)-7-methyl-3 ,7-dihydro-pyrrolo [2 ,3 -d]pyrimidin-4-one, 2-(6-Ethoxy-pyridin-3-yl)-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one, 7-Methyl-2-pyridin-3-yl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one, 7-Methyl-2-(6-methyl-pyridin-3-yl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one, 4-(7-Methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)-benzonitrile, 7-Methyl-2-(6-trifluoromethyl-pyridin-3-yl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin- l-Methyl-6-(4-trifluoromethyl-phenyl)-l,5-dihydro-pyrrolo[3,2-c]pyridin-4-one,

1- Ethyl-6-(4-trifluoromethyl-phenyl)-l,5-dihydro-pyrrolo[3,2-c]pyridin-4-one,

1 -Methyl-6-(l -methyl- lH-pyrazol-4-yl)- 1 ,5 -dihydro-pyrrolo [3 ,2-c]pyridin-4-one,

2- [4-(4-Fluoro-phenyl)-piperidin-l-yl]-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4- one,

7-But-3-enyl-2-(4-trifluoromethyl-phenyl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one,

7-Ethyl-2-(4-trifluoromethyl-phenyl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one, 7-Propyl-2-(4^rifluoromethyl^henyl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one,

7-Allyl-2-(4^rifluoromethyl^henyl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one,

7-(3,4-Dihydroxy-butyl)-2-(4-trifluoromethyl-phenyl)-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4 -one ,

7-(2,3-Dihydroxy-propyl)-2-(4-trifiuoromethyl-phenyl)-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4 -one ,

7-Methyl-2-pyrazol- 1 -yl-3 ,7-dihydro-pyrrolo[2 ,3 -d]pyrimidin-4-one, 7-Hydroxymethyl-2-(4-trifluoromethyl-phenyl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4- one,

2-[4-(2,6-Difluoro-phenyl)-piperazin-l-yl]-7-(2,3-dihydroxy-propyl)-3,7-dihydro- pyrrolo[2,3-d]pyrimidin-4-one and

7-Methyl-2-phenyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one.

In another embodiment of the present invention there is provided a compound according to formula I which compound is 2-[4-[2 6-difiuoro-4-(2-methoxyethoxy)phenyl]piperazin-l-yl]- 7-(2 -hydroxyethyl)-3 H-pyrrolo [2 3 -d]pyrimidin-4-one .

In another embodiment of the present invention there is provided a method of inhibiting tankyrase 1 and/or tankyrase 2 by contacting either or both with a compound of formula I wherein Ri, R₂ and Q are as defined hereinabove. In another embodiment of the present invention there is provided a method of treating cancer by administering to a patient in need thereof a therapeutically active amount of a compound of formula I wherein Ri, R₂ and Q are as defined hereinabove.

In another embodiment of the present invention there is provided a method of treating colorectal by administering to a patient in need thereof a therapeutically active amount of a compound of formula I wherein Ri, R₂ and Q are as defined hereinabove.

In another embodiment of the present invention there is provided a compound of formula I wherein Ri, R₂ and Q are as defined hereinabove for use in the preparation of a medicament for the treatment of cancer. In another embodiment of the present invention there is provided a pharmaceutical composition comprising a compound of formula I wherein Ri, R₂ and Q are as defined hereinabove and at least one pharmaceutically acceptable carrier, diluent and/or excipient.

Definitions

As used herein, the following terms shall have the following definitions. The term "alkyl" refers to straight- or branched-chain saturated hydrocarbon groups having from 1 to about 12 carbon atoms, including groups having from 1 to about 7 carbon atoms. In certain embodiments, alkyl substituents may be lower alkyl substituents. The term "lower alkyl" refers to alkyl groups having from 1 to 6 carbon atoms ("Ci_₆alkyl"), preferably from 1 to 4 carbon atoms

Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, and s-pentyl.

The term "alkenyl" as used herein means an unsaturated straight-chain or branched aliphatic hydrocarbon group containing at least one double bond and having 2 to 6 ("C₂- ₆alkenyl"), preferably 2 to 4 carbon atoms ("C₂-₄alkenyl"). Examples of such an "alkenyl group" are vinyl, ethenyl, allyl, isopropenyl, 1-propenyl, 2-methyl-l-propenyl, 1-butenyl, 2-butenyl, 3- butenyl, 2-ethyl- 1-butenyl, 3-methyl-2-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 4-methyl-3-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl and 5-hexenyl.

The term "alkoxy" as used herein means an -O-alkyl group which is attached to the remainder of the molecule by an oxygen atom, wherein alkyl is as defined above such as methoxy, ethoxy, «-propyloxy, z^'-propyloxy, «-butyloxy, z^'-butyloxy, i-butyloxy, pentyloxy, hexyloxy, including their isomers. "Lower alkoxy" as used herein denotes an alkoxy group with a "lower alkyl" group as previously defined. "Cno alkoxy" as used herein refers to an-O-alkyl wherein alkyl is C_1-10, "Ci-6 alkoxy" as used herein refers to an-O-alkyl wherein alkyl is Ci_6.

The term "alkynyl" as used herein means an unsaturated straight-chain or branched aliphatic hydrocarbon group containing one triple bond and having 2 to 6 ("C₂-₄alkynyl"), preferably 2 to 4 carbon atoms ("C₂-₄alkynyl"). Examples of such "alkynyl group" are ethynyl, 1- propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4- pentynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl and 5-hexynyl.

Amino means the group -NH₂.

The term "aryl" as used herein denotes a monovalent aromatic carbocyclic radical containing 6 to 10 carbon atoms consisting of one individual ring, or one or more fused rings wherein the fused rings may be aromatic, partially unsaturated or saturated and wherein the aryl is attached to the remainder of the molecule at the aromatic ring. An aryl group can optionally be substituted with one or more, preferably one to three substituents independently selected from hydroxy, thio, cyano, alkyl, alkoxy, lower haloalkoxy, alkylthio, halogen, haloalkyl, hydroxyalkyl, nitro, alkoxycarbonyl, amino, alkylamino, dialkylamino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkylsulfonyl, arylsulfinyl, alkylaminosulfonyl, arylaminosulfonyl, alkylsulfonylamido, arylsulfonylamido, carbamoyl, alkylcarbamoyl dialkylcarbamoyl, arylcarbamoyl, alkylcarbonylamino and arylcarbonylamino, unless otherwise indicated. Alternatively two adjacent atoms of the aryl ring may be substituted with a methylenedioxy or ethylenedioxy group. Examples of aryl radicals include phenyl, naphthyl, indanyl, 3,4-methylenedioxyphenyl, 1 ,2,3,4-tetrahydroquinolin-7-yl, l,2,3,4-tetrahydroisoquinoline-7-yl, and the like. A particular example is phenyl.

Carboxyl or carboxy means the monovalent group -C(=0)OH.

The terms "alkoxycarbonyl" and "aryloxycarbonyl" as used herein denotes a group of - C(=0)OR wherein R is alkyl or aryl respectively and alkyl and aryl are as defined herein.

Carbonyl means the group R'C(=0)R" where R' and R" independently can be any of a number of chemical groups including alkyl. The term "acyl", "alkanoyl" or "alkylcarbonyl" as used herein denotes a group of formula -C(=0)R wherein R is hydrogen or lower alkyl as defined herein. The term Ci_6 acyl [or "alkanoyl"] refers to a group -C(=0)R contain 1 to 6 carbon atoms. The Ci acyl or "alkanoyl" group is the formyl group wherein R = H. The term "arylcarbonyl" or "aroyl" as used herein means a group of formula C(=0)R wherein R is an aryl group; the term "benzoyl" as used herein an "arylcarbonyl" or "aroyl" group wherein R is phenyl. The term "cycloalkyl" as used herein means any stable monocyclic or polycyclic system which consists of carbon atoms only, any ring of which being saturated, and the term "cycloalkenyl" is intended to refer to any stable monocyclic or polycyclic system which consists of carbon atoms only, with at least one ring thereof being partially unsaturated. Examples of cycloalkyls include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclooctyl, bicycloalkyls, including bicyclooctanes such as [2.2.2]bicyclooctane or [3.3.0]bicyclooctane, bicyclononanes such as [4.3.0]bicyclononane, and bicyclodecanes such as [4.4.0]bicyclodecane (decalin), or spiro compounds. Examples of cycloalkenyls include, but are not limited to, cyclopentenyl or cyclohexenyl. A particular example is cyclopropyl.

The term "halogen" as used herein means fluoro, chloro, bromo, or iodo, preferably fluoro and chloro.

"Heteroaryl" means an aromatic heterocyclic ring system containing up to two rings. In one embodiment of the invention heteroaryl groups include, but are not limited to, thienyl, furyl, indolyl, pyrrolyl, pyridinyl, pyrazinyl, oxazolyl, thiaxolyl, quinolinyl, pyrimidinyl, imidazole substituted or unsubstituted triazolyl and substituted or unsubstituted tetrazolyl. Particular examples are pyridinyl, pyrazinyl or pyrimidinyl.

"Hetero atom" means an atom selected from N, O and S.

"Heterocycle" or "heterocyclic ring" means a substituted or unsubstituted 5 to 8 membered, mono- or bicyclic, non-aromatic hydrocarbon, wherein 1 to 3 carbon atoms are replaced by a hetero atom selected from nitrogen, oxygen or sulfur atom. When the heterocycle is bicyclic one ring can lack a heteroatom and be aromatic, partially unsaturated or saturated but heterocycle is attached to the remainder of the molecule at the heterocyclic ring. Examples include pyrrolidin-2-yl; pyrrolidin-3-yl; piperidinyl; morpholin-4-yl and the like which in turn can be substituted.

Hydroxy or hydroxyl is a prefix indicating the presence of a monovalent -OH group.

"Lower" as in "lower alkenyl" means a group having 1 to 6 carbon atoms.

"Nitro" means -N0₂.

"Oxo" means the group =0. The terms "alkylsulfonyl" and "arylsulfonyl" as used herein denotes a group of formula - S(=0)₂R wherein R is alkyl or aryl respectively and alkyl and aryl are as defined herein. The terms Ci_6 haloalkylsulfonyl, C3-7 cycloalkylsulfonyl, C3-7 cycloalkyl-Ci-3 alkyl-sulfonyl or Ci_6 alkoxy-Ci-6 alkylsulfonyl refer to a compound, S(=0)₂R wherein R is Ci_6 haloalkyl, C3-7 cycloalkyl, C3-7 cycloalkyl-Ci-3 alkyl and Ci_6 alkoxy-Ci-6 alkyl, respectively.

The terms "hydroxyalkyl" and "alkoxyalkyl" as used herein denotes alkyl radical as herein defined wherein one hydrogen atom is replaced by a hydroxyl. A C₁-3 alkoxy-Ci-6 alkyl moiety refers to a Ci_6 alkyl substituent in which 1 to 3 hydrogen atoms are replaced by a C₁-3 alkoxy and the point of attachment of the alkoxy is the oxygen atom. "Dihydroxyalkyl" as used herein denotes alkyl radical as herein defined wherein two hydrogen atoms on different carbon atoms are replaced by hydroxyl.

The term "haloalkyl" as used herein denotes an alkyl group as defined above wherein at least one hydrogen atom is substituted by a halogen. Examples are 1 -fluoromethyl, 1- chloromethyl, 1-bromomethyl, 1-iodomethyl, difluoromethyl, trifiuoromethyl, trichloromethyl, 1-fluoroethyl, 1-chloroethyl, 2-fiuoroethyl, 2-chloroethyl, 2-bromoethyl, 2,2-dichloroethyl, 3- bromopropyl or 2,2,2 -trifluoroethyl.

The term "haloalkyl" as used herein denotes an alkyl group as defined above wherein at least one hydrogen atom is substituted by a halogen. Examples are 1 -fluoromethyl, 1- chloromethyl, 1-bromomethyl, 1-iodomethyl, difluoromethyl, trifiuoromethyl, trichloromethyl, 1-fluoroethyl, 1-chloroethyl, 2-fluoroethyl, 2-chloroethyl, 2-bromoethyl, 2,2-dichloroethyl, 3- bromopropyl or 2,2 ,2 -trifluoroethyl

The term "alkoxyalkyl" as used herein refers to the radical R'R"-, wherein R' is an alkoxy radical as defined herein, and R" is an alkylene radical as defined with the understanding that the attachment point of the alkoxyalkyl moiety will be on the alkylene radical. Ci_6 alkoxyalkyl denotes a group wherein the alkyl portion is comprised of 1 -6 carbon atoms exclusive of carbon atoms in the alkoxy portion of the group. C₁-3 alkoxy-Ci-6 alkyl denotes a group wherein the alkyl portion is comprised of 1-6 carbon atoms and the alkoxy group is 1 -3 carbons. Examples include, but are not limited to, methoxymethyl, methoxyethyl, methoxypropyl, ethoxyethyl, ethoxypropyl, propyloxypropyl, methoxybutyl, ethoxybutyl, butyloxybutyl, i-butyloxybutyl, ethoxypentyl, propyloxypentyl including their isomers .

The term "alkylene" as used herein denotes a divalent saturated linear hydrocarbon radical of 1 to 10 carbon atoms (e.g., (CH₂)_n)or a branched saturated divalent hydrocarbon radical of 2 to 10 carbon atoms (e.g., -CHMe- or -CH₂CH(z^'-Pr)CH₂-), unless otherwise indicated. Co-4 alkylene or (alkylene)o-4 refers to a linear or branched saturated divalent hydrocarbon radical comprising 1-4 carbon atoms or, in the case of Co, the alkylene radical is omitted. Except in the case of methylene, the open valences of an alkylene group are not attached to the same atom. "Pharmaceutically acceptable," such as pharmaceutically acceptable carrier, excipient, etc., means pharmacologically acceptable and substantially non-toxic to the subject to which the particular compound is administered.

"Pharmaceutically acceptable salt" refers to conventional acid-addition salts or base- addition salts that retain the biological effectiveness and properties of the compounds of the present invention and are formed from suitable non-toxic organic or inorganic acids or organic or inorganic bases. Sample acid-addition salts include those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, phosphoric acid and nitric acid, and those derived from organic acids such as p-toluenesulfonic acid, salicylic acid, methanesulfonic acid, oxalic acid, succinic acid, citric acid, malic acid, lactic acid, fumaric acid, trifluoro acetic acid and the like. Sample base-addition salts include those derived from ammonium, potassium, sodium and, quaternary ammonium hydroxides, such as for example, tetramethylammonium hydroxide. Chemical modification of a pharmaceutical compound (i.e. drug) into a salt is a technique well known to pharmaceutical chemists to obtain improved physical and chemical stability, hygroscopicity, flowability and solubility of compounds. See, e.g., Ansel et al, Pharmaceutical Dosage Forms and Drug Delivery Systems (1995) at pgs. 456-457.

The compounds of the invention may be administered by any suitable means, including oral, topical (including buccal and sublingual), rectal, vaginal, transdermal, parenteral, subcutaneous, intraperitoneal, intrapulmonary, intradermal, intrathecal and epidural and intranasal, and, if desired for local treatment, intralesional administration. Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration.

The compounds of the present invention may be administered in any convenient administrative form, e.g., tablets, powders, capsules, solutions, dispersions, suspensions, syrups, sprays, suppositories, gels, emulsions, patches, etc. Such compositions may contain components conventional in pharmaceutical preparations, e.g., diluents, carriers, pH modifiers, sweeteners, bulking agents, and further active agents. A typical formulation is prepared by mixing a compound of the present invention and a carrier or excipient. Suitable carriers and excipients are well known to those skilled in the art and are described in detail in, e.g., Ansel, Howard C, et al., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems. Philadelphia: Lippincott, Williams & Wilkins, 2004; Gennaro, Alfonso R., et al. Remington: The Science and Practice of Pharmacy. Philadelphia: Lippincott, Williams & Wilkins, 2000; and Rowe, Raymond C. Handbook of Pharmaceutical Excipients. Chicago, Pharmaceutical Press, 2005. The formulations may also include one or more buffers, stabilizing agents, surfactants, wetting agents, lubricating agents, emulsifiers, suspending agents, preservatives, antioxidants, opaquing agents, glidants, processing aids, colorants, sweeteners, perfuming agents, flavoring agents, diluents and other known additives to provide an elegant presentation of the drug (i.e., a compound of the present invention or pharmaceutical composition thereof) or aid in the manufacturing of the pharmaceutical product (i.e., medicament).

An embodiment, therefore, includes a pharmaceutical composition comprising a compound of Formula I, or a stereoisomer or pharmaceutically acceptable salt thereof. In a further embodiment includes a pharmaceutical composition comprising a compound of Formula I, or a stereoisomer or pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or excipient.

Another embodiment includes a pharmaceutical composition comprising a compound of Formula I for use in the treatment of a hyperproliferative disease. Another embodiment includes a pharmaceutical composition comprising a compound of Formula I for use in the treatment of cancer.

"Substituted," as in substituted alkyl, means that the substitution can occur at one or more positions and, unless otherwise indicated, that the substituents at each substitution site are independently selected from the specified options. The term "optionally substituted" refers to the fact that one or more hydrogen atoms of a chemical group (with one or more hydrogen atoms) can be, but does not necessarily have to be, substituted with another substituent. In the specification where indicated the various groups may be substituted by preferably, 1-3 substituents independently selected from the group consisting of H, carboxyl, amido, hydroxyl, alkoxy, substituted alkoxy, sulfide, sulfone, sulfonamide, sulfoxide, halogen, nitro, amino, substituted amino, lower alkyl, substituted lower alkyl, lower cycloalkyl, substituted lower cycloalkyl, lower alkenyl, substituted lower alkenyl, lower cycloalkenyl, substituted lower cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle or substituted heterocycle. In general, the nomenclature used in this Application is based on AUTONOM v.4.0, a Beilstein Institute computerized system for the generation of IUPAC systematic nomenclature. If there is a discrepancy between a depicted structure and a name given that structure, the depicted structure is to be accorded more weight. In addition, if the stereochemistry of a structure or a portion of a structure is not indicated with, for example, bold or dashed lines, the structure or portion of the structure is to be interpreted as encompassing all stereoisomers of it.

Compounds in following schemes are depicted with generalized substituents; however, one skilled in the art will immediately appreciate that the nature of the R groups can varied to afford the various compounds contemplated in this invention. Moreover, the reaction conditions are exemplary and alternative conditions are well known. The reaction sequences in the following examples are not meant to limit the scope of the invention as set forth in the claims.

SCHEME A

Base,

A-1 A-2 A-3

Y = N or CH

Nucleophilic Displacement

A-4

The compounds of formula A-2 where Ri is hydrogen and Y is nitrogen or carbon can be purchased from commercial sources.

The compound of formula A-2 where Ri is lower alkyl or alkenyl and where Y is nitrogen or carbon can be prepared by reacting the appropriate heterocyclic starting material with a commercially available or a synthetically prepared halide of the corresponding lower alkyl or alkenyl derivative under basic conditions (see for example, Chuaqui, C. E.; Huang, S.; Ioannidis, S.; Shi, J.; Su, M.; Su, Q., WO2010/038060 Al; Bursavich, M. G.; Nowak, P. W.; Malwitz, D.; Lombardi, S.; Gilbert, A. M.; Zhang, N.; Ayral-Kaloustian, S.; Anderson, J. T.; Brooijmans, N., US2010/0015141A1). The lower alkyl or alkenyl derivative may be in a protected form that may be deprotected at some point in the synthesis. The lower alkyl or alkenyl derivative could also be transformed through standard chemical manipulation. The compound of formula A-2 where Ri is cycloalkyl and where Y is nitrogen or carbon can be prepared by reacting the appropriate amine compound with a commercially available or a synthetically prepared boronic acid or boronate ester of the corresponding cycloalkyl derivative under metal catalyzed coupling conditions (see for example, Dillon, M.P., Du Bois, D.J., Lai, Y., Hawley, R.C., Wang, B., US 2010/0144758). The cycloalkyl group may be in a protected form that may be deprotected at some point in the synthesis.

The compound of formula A-3 where Ri is hydrogen and where Y is nitrogen can be prepared from the compound of formula A-2 where Ri is hydrogen by heating under basic aqueous conditions (Zhang, Z., Wallace, M.B., Feng, J., Stafford, J.A., Skene, R.J., Shi, L., Lee, B., Aertgeerts, K., Jennings, A., Xu, R., Kassel, D.B., Kaldor, S.W., Navre, M., Webb, D.R., Gwaltney, S.L,II , J. Med. Chem., 201 1 , 54(2), 510-524).

The compound of formula A-3 where Ri is lower alkyl, alkenyl or cycloalkyl and where

Y is nitrogen or carbon can be prepared from the compound of formula A-2 where Ri is lower alkyl, alkenyl or cycloalkyl, Y is nitrogen or carbon by heating under basic aqueous condition (see for example, Zhang, Z., Wallace, M.B., Feng, J., Stafford, J.A., Skene, R.J., Shi, L., Lee, B., Aertgeerts, K., Jennings, A., Xu, R., Kassel, D.B., Kaldor, S.W., Navre, M., Webb, D.R., Gwaltney, S.L,II , J. Med. Chem., 2011 , 54(2), 510-524). The lower alkyl, alkenyl or cycloalkyl group may be in a protected form that may be deprotected at some point in the synthesis. The lower alkyl or alkenyl derivative could also be transformed through standard chemical manipulation. The compound of formula A-4 where Ri is lower alkyl, alkenyl or cycloalkyl and where

Y is nitrogen or carbon and R₂ is an appropriately substituted secondary or tertiary amino group can be prepared from the compound of formula A-3where Ri is lower alkyl, alkenyl or cycloalkyl and where Y is nitrogen or carbon through nucleophilic displacement of the chloro of the compound of formula A-3 with an appropriately substituted primary or secondary amino group (see for example, Ram, V.J., Farhanullah, Tripathi, B.K., Srivastava, A.K., Bioorg. Med. Chem., 2003, 11, 2439-2444). The amine reagent may be appropriately protected or functionalized such that upon displacement of the chloro the protecting group could be removed and/or the various functionalities could be further elaborated. The amine reagent may be commercially available or may be prepared through standard synthetic manipulation. The lower alkyl, alkenyl or cycloalkyl derivative of Ri may be in a protected form that may be deprotected at some point in the synthesis. The lower alkyl, alkenyl or cycloalkyl derivative of Ri derivative could also be transformed through standard chemical manipulation.

The compound of formula A-4 where Ri is lower alkyl, alkenyl or cycloalkyl and where

Y is nitrogen or carbon and R₂ is aryl, substituted aryl, heteroaryl or substituted heteroaryl can be prepared from the compound of formula A-3 where Ri is lower alkyl, alkenyl or cycloalkyl and where Y is nitrogen or carbon through a metal catalyzed coupling reaction using a reagent containing a boronic acid or boronate ester of a aryl, substituted aryl, heteroaryl or substituted heteroaryl (see for example, Denny, W.A., Baguley, B.C., Marshall, E.S., Sutherland, H.S., WO2007/117161 Al). The lower alkyl, alkenyl or cycloalkyl derivative of Ri may be in a protected form that may be deprotected at some point in the synthesis. The lower alkyl, alkenyl or cycloalkyl derivative of Ri derivative could also be transformed through standard chemical manipulation. The compound of formula A-4 where Ri is hydrogen and where Y is nitrogen and R₂ is aryl, substituted aryl, heteroaryl or substituted heteroaryl can be prepared from the compound of formula A-3 where Ri is hydrogen and where Y is nitrogen or carbon through a metal catalyzed coupling reaction using a reagent containing a boronic acid or boronate ester of a aryl, substituted aryl, heteroaryl or substituted heteroaryl (see for example, Denny, W.A., Baguley, B.C., Marshall, E.S., Sutherland, H.S., WO2007/117161 Al).

The following preparations and examples are given to enable those skilled in the art to more clearly understand and to practice the present invention. They should not be considered as limiting the scope of the invention, but merely as being illustrative and representative thereof.

Abbreviations

Ac₂0 Acetic anhydride

AcOH Acetic acid

DBU 1 ,8-Diazabicyclo[5.4.0]undec-7-ene

DCE 1 ,2-Dichloroethane

DCM Dichloromethane/Methylene chloride DIPEA Diisopropylethylamine

DMF N,N-dimethylformamide

DMSO Dimethyl sulfoxide

EDCI l-(3-Dimethylaminopropyl)-3-ethylcarbodiimide Et₂0 Diethyl ether

EtOH Ethanol/Ethyl alcohol

EtOAc Ethyl acetate

IWR2 4-((lS,2R,6S,7R)-3,5-Dioxo-4-aza-tricyclo[5.2.1.0*2,6*]dec-8-en-4-yl)- N-(4-methyl-quinolin-8-yl)-benzamide HOBt 1-Hydroxybenzotriazole

LDA Lithium diisopropylamide

LiHMDS Lithium bis(trimethylsilyl)amide m-CPBA 3-Chloroperoxybenzoic acid

MeOH Methanol/Methyl alcohol MW Molecular Weight

NMP 1 -Methyl-2 -pyrro lidinone

PMB 4-Methoxy benzyl

RT Room temperature

TBME tert- utyl methyl ether TFA Trifluoroacetic acid

Tf₂0 Trifluoromethanesulfonic anhydride

THF Tetrahydrofuran TLC Thin layer chromatography

TNKS Tankyrase

Tris 2-amino-2-hydroxymethyl-propane- 1 ,3-diol

XAV939 2-(4-Trifiuoromethyl-phenyl)-3,5,7,8-tetrahydro-thiopyrano[4,3- d]pyrimidin-4-one

General Conditions

Compounds of the invention can be made by a variety of methods depicted in the illustrative synthetic reactions described below in the Examples section.

The starting materials and reagents used in preparing these compounds generally are either available from commercial suppliers, such as Aldrich Chemical Co., or are prepared by methods known to those skilled in the art following procedures set forth in references such as Fieser and Fieser's Reagents for Organic Synthesis; Wiley & Sons: New York, 1991,

Volumes 1-15; Rodd's Chemistry of Carbon Compounds, Elsevier Science Publishers, 1989, Volumes 1-5 and Supplementals; and Organic Reactions, Wiley & Sons: New York, 1991, Volumes 1-40. It should be appreciated that the synthetic reaction schemes shown in the Examples section are merely illustrative of some methods by which the compounds of the invention can be synthesized, and various modifications to these synthetic reaction schemes can be made and will be suggested to one skilled in the art having referred to the disclosure contained in this application.

The starting materials and the intermediates of the synthetic reaction schemes can be isolated and purified if desired using conventional techniques, including but not limited to, filtration, distillation, crystallization, chromatography, and the like. Such materials can be characterized using conventional means, including physical constants and spectral data.

Unless specified to the contrary, the reactions described herein are typically conducted under an inert atmosphere at atmospheric pressure at a reaction temperature range of from about

78°C to about 150°C, often from about 0°C to about 125°C, and more often and conveniently at about room (or ambient) temperature, e.g., about 20°C. Preparative reverse-phase high-pressure liquid chromatography (RP HPLC) was performed using one of the following systems: (A), a Waters Delta prep 4000 pump / controller, a 486 detector set at 215 nm, and a LKB Ultrorac fraction collector; or (B). a Sciex LC/MS system with a 150 EX single quad mass spec, a Shimadzu LC system, a LEAP autoinjector, and a Gilson fraction collector. The sample was dissolved in a mixture of acetonitrile / 20 mM aqueous ammonium acetate or acetonitrile / water / TFA, applied on a Pursuit C- 18 20 x 100 mm column and eluted at 20 mL/min with a linear gradient of 10%-90% B, where (A): 20 mM aqueous ammonium acetate (pH 7.0) and (B): acetonitrile or (A): water with 0.05% TFA and (B): acetonitrile with 0.05% TFA. Flash chromatography was performed using standard silica gel chromatography, prepacked silica columns (Analogix) with an Analogix BSR pump system or AnaLogix IntelliFlash Automated systems. Reactions heated in a microwave were performed using the Biotage Initiator 60 microwave or the CEM Explore microwave.

PREPARATIVE EXAMPLES Intermediate A

2-Chloro-7-methyl-3 ,7-dihydro-pyrrolo[2 ,3 -d]pyrimidin-4-one

Step 1 : A solution of 2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine (3.00 g, 16.0 mmol) in anhydrous tetrahydrofuran (45 mL) was cooled to 0°C and treated with a 60%> dispersion of sodium hydride in mineral oil (0.83 g, 20.8 mmol). The reaction was stirred at 0°C for 20-30 min. The reaction was then treated with iodomethane (3.65 g, 1.6 mL, 25.7 mmol), and the reaction stirred at room temperature overnight. The reaction was diluted with a saturated aqueous ammonium chloride solution (50 mL) and water (50 mL) and was extracted with a 10% methanol in methylene chloride solution (4 x 50 mL). The combined organic layers were dried over magnesium sulfate, filtered and rinsed with methylene chloride, and concentrated in vacuo onto Celite®. Flash chromatography (80 g silica gel column, 0-15% ethyl acetate/hexanes) afforded 2,4-dichloro-7-methyl-7H-pyrrolo[2,3-d]pyrimidine as a light yellow solid (2.39 g, 74.1%). 1H NMR (400 MHz, DMSO-d₆) δ ppm 3.81 (s, 3 H) 6.70 (d, J=3.51 Hz, 1 H) 7.76 (d, J=3.51 Hz, 1 H). LC-MS calcd. for C₇H₆CI₂N₃ [(M+H)⁺] 202, obsd. 202.0. Step 2: 2,4-dichloro-7-methyl-7H-pyrrolo[2,3-d]pyrimidine (2.39 g, 11.8 mmol) was treated with a 2M aqueous potassium hydroxide solution (70 mL, 140 mmol). The reaction was warmed to 100°C, where it was stirred overnight. The reaction was allowed to cool down to room temperature gradually, where it stirred for an additional 2 nights. The reaction was brought to ρΗ ~ 7-8 with a 3N aqueous hydrochloric acid solution. The resulting light yellow mixture was cooled in an ice/water bath and filtered, rinsing twice with a small amount of water. The filtrate was brought to pH ~2-3 with additional 3N aqueous hydrochloric acid solution. The resulting opaque light yellow mixture was filtered through the original filter cake. The solids were dried in vacuo to afford 2-chloro-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one as an off-white solid (2.18 g, 100%). ^!H NMR (300 MHz, DMSO-d₆) δ ppm 3.67 (s, 3 H) 6.46 (d, J=3.39 Hz, 1 H) 7.11 (d, J=3.39 Hz, 1 H) 12.83 (br. s., 1 H). LC-MS calcd. for C₇H₇C1N₃0 [(M+H)⁺] 184, obsd. 183.9.

In an analogous manner to the stepwise sequence outlined for the synthesis of Intermediate A, the following compounds were prepared as follows:

Intermediate B

7-But-3-enyl-2-chloro-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one

From 2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine and 4-bromobut-l-ene: crude 7-(but-3- enyl)-2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine was obtained as a light brown solid (0.66 g, 85.4%). 1H NMR (300 MHz, DMSO-d₆) δ ppm 2.47 - 2.68 (m, 2 H) 4.31 (t, J=6.97 Hz, 2 H) 4.80 - 5.16 (m, 2 H) 5.59 - 5.93 (m, 1 H) 6.70 (d, J=3.58 Hz, 1 H) 7.82 (d, J=3.58 Hz, 1 H).

From crude 7-(but-3-enyl)-2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine: 7-but-3-enyl-2- chloro-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one was obtained as a light yellow solid (184.3 mg, 30.2%). 1H NMR (300 MHz, DMSO-d₆) δ ppm 2.43 - 2.56 (m, 2 H) 4.14 (t, J=7.06 Hz, 2 H) 4.81 - 5.16 (m, 2 H) 5.75 (ddt, J=17.10, 10.31, 6.64, 6.64 Hz, 1 H) 6.46 (d, J=3.39 Hz, 1 H) 7.17 (d, J=3.39 Hz, 1 H) 12.84 (br. s., 1 H). LC-MS calcd. for Ci₀HnClN₃O [(M+H)⁺] 224, obsd. 224.0. Intermediate C

2-Chloro-7-ethyl-3 ,7-dihydro-pyrrolo[2 ,3 -d]pyrimidin

From 2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine and iodoethane: 2,4-dichloro-7-ethyl- 7H-pyrrolo[2,3-d]pyrimidine was obtained as a white solid (129.1 mg, 74.9%). ^!H NMR (300 MHz, DMSO- e) δ ppm 1.38 (t, J=7.35 Hz, 3 H) 4.26 (q, J=7.22 Hz, 2 H) 6.71 (d, J=3.58 Hz, 1 H) 7.85 (d, J=3.58 Hz, 1 H). LC-MS calcd. for C₈H₈C1₂N3 [(M+H)⁺] 216, obsd. 215.8.

From 2,4-dichloro-7-ethyl-7H-pyrrolo[2,3-d]pyrimidine: 2-chloro-7-ethyl-3,7-dihydro- pyrrolo[2,3-d]pyrimidin-4-one was obtained as an off-white solid (96.4 mg, 84.3%). 1H NMR (300 MHz, DMSO-de) δ ppm 1.32 (t, J=7.25 Hz, 3 H) 4.10 (q, J=7.22 Hz, 2 H) 6.47 (d, J=3.39 Hz, 1 H) 7.19 (br. s., 1 H) 12.83 (br. s., 1 H). LC-MS calcd. for C₈H₉C1N₃0 [(M+H)⁺] 198, obsd. 197.9.

Intermediate D

2-Chloro-7-propyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-

From 2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine and 1-iodopropane: 2,4-dichloro-7- propyl-7H-pyrrolo[2,3-d]pyrimidine was obtained as a light yellow semi-solid (122.4 mg, 50%>). ^!H NMR (300 MHz, DMSO-d₆) δ ppm 0.83 (br. s., 3 H) 1.80 (br. s., 2 H) 4.19 (br. s., 2 H) 6.71 (br. s., 1 H) 7.83 (br. s., 1 H). LC-MS calcd. for C₉Hi₀Cl₂N₃ [(M+H)⁺] 230, obsd. 229.87.

From 2,4-dichloro-7-propyl-7H-pyrrolo[2,3-d]pyrimidine: 2-chloro-7-propyl-3,7- dihydro-pyrrolo[2,3-d]pyrimidin-4-one was obtained as a light yellow solid (104.3 mg, 94.5%>). 1H NMR (400 MHz, DMSO-d₆) δ ppm 0.81 (t, J=7.42 Hz, 3 H) 1.73 (sxt, J=7.27 Hz, 2 H) 4.01 (t, J=7.23 Hz, 2 H) 6.46 (d, J=3.52 Hz, 1 H) 7.15 (br. s., 1 H) 12.82 (br. s., 1 H). LC-MS calcd. for C₉HiiClN₃0 [(M+H)⁺] 212, obsd. 212.0. Intermediate E

7-Allyl-2-chloro-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one

From 2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine and 3-iodoprop-l-ene: 7-allyl-2,4- dichloro-7H-pyrrolo[2,3-d]pyrimidine was obtained as a light yellow solid (130.1 mg, 53.6%). ^!H NMR (400 MHz, DMSO-d₆) δ ppm 4.88 (dt, J=5.37, 1.61 Hz, 2 H) 4.99 (dq, J=17.09, 1.46 Hz, 1 H) 5.20 (dq, .7=10.30, 1.38 Hz, 1 H) 6.04 (ddt, J=17.09, 10.45, 5.37, 5.37 Hz, 1 H) 6.75 (d, J=3.52 Hz, 1 H) 7.76 (d, J=3.91 Hz, 1 H). LC-MS calcd. for C₉H₈C1₂N₃ [(M+H)⁺] 228, obsd. 227.9. From 7-allyl-2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine: 7-allyl-2-chloro-3,7-dihydro- pyrrolo[2,3-d]pyrimidin-4-one was obtained as a light yellow solid (104.4 mg, 88.7%). ^!H NMR (400 MHz, DMSO- e) δ ppm 4.72 (d, J=5.47 Hz, 2 H) 4.97 (dd, J=17.19, 1.56 Hz, 1 H) 5.17 (dd, J=10.16, 1.56 Hz, 1 H) 5.92 - 6.11 (m, 1 H) 6.52 (d, .7=3.13 Hz, 1 H) 7.12 (br. s., 1 H) 12.89 (br. s., 1 H). LC-MS calcd. for C₉H₉CIN₃O [(M+H)⁺] 210, obsd. 209.9. Intermediate F

2-Chloro-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one

A solution of 2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine (400 mg, 2.13 mmol) in a 2M aqueous potassium hydroxide solution (12 mL) was heated to 100°C for 4 h. At this time, the resulting mixture was poured onto iced water and then acidified to pH 6.5 with a 6M aqueous hydrochloric acid solution. The acidic solution was extracted with ethyl acetate. The combined organics were washed with a saturated aqueous sodium chloride solution, dried over sodium sulfate, filtered and concentrated in vacuo. The resulting residue was triturated with acetonitrile and ether to afford 2-chloro-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one. ^!HNMR (400 MHz, DMSO- e) δ ppm 6.40 - 6.48 (m, 1 H) 7.01 - 7.10 (m, 1 H) 12.0 (s, 1 H) 12.8 (s, 1 H). Intermediate G

6-Chloro-l -methyl- 1 ,5-dihydro-pyrrolo[3 ,2-c]pyridine-4-one

Step 1 : A solution of 4,6-dichloro-lH-pyrrolo[3,2-c]pyridine (270 mg, 1.44 mmol) in tetrahydrofuran (4 mL) at 0°C was treated with a 60% dispersion of sodium hydride in mineral oil (69.3 mg, 2.89 mmol) followed by iodomethane (225 mg, 1.59 mmol). After stirring at 0°C for 0.5 h, the reaction mixture was allowed to warm to room temperature and was stirred at room temperature for 5 h. At this time, the resulting mixture was quenched with a saturated aqueous sodium bicarbonate solution. The reaction mixture was extracted with ethyl acetate. The combined organics were washed with a saturated aqueous sodium chloride solution, dried over sodium sulfate, filtered and concentrated in vacuo. Flash chromatography (30% ethyl acetate/hexanes) afforded 4,6-dichloro-l -methyl- lH-pyrrolo[3,2-c]pyridine (278 mg, 95.8%). LC-MS calcd. for

[(M+H)⁺] 201 , obsd. 200.8.

Step 2: A microwave reaction vial was charged with 4,6-dichloro-l -methyl- 1H- pyrrolo[3,2-c]pyridine (60 mg, 0.29 mmol), a 2M aqueous sodium hydroxide solution (10 mL) and 1,4-dioxane (1 mL). The vial was sealed and then heated in the microwave at 160°C for 30 min. At this time, the resulting mixture was acidified to pH 6.5 with a 4M aqueous hydrochloric acid solution and then concentrated in vacuo. The residue was diluted with ethanol. The solids were removed by filtration, and the filtrate was concentrated in vacuo. Flash chromatography (10/1 methylene chloride/methanol) afforded 6-chloro-l-methyl-l ,5-dihydro-pyrrolo[3,2- c]pyridine-4-one (51 mg, 93.6%). LC-MS calcd. for C₈H₇C1N₂02 [(M+H)⁺] 183, obsd. 182.9.

Intermediate H

6-Chloro-l -ethyl- 1 ,5-dihydro-pyrrolo[3 ,2-c]pyridine-

Step 1 : A solution of 4,6-dichloro-lH-pyrrolo[3,2-c]pyridine (250 mg, 1.34 mmol) in tetrahydrofuran (4 niL) at 0°C was treated with a 60% dispersion of sodium hydride in mineral oil (64.2 mg, 2.67 mmol) followed by iodoethane (229 mg, 1.47 mmol). After stirring at 0°C for 0.5 h, the reaction mixture was allowed to warm to room temperature and was stirred at room temperature overnight. At this time, the resulting mixture was quenched with a saturated aqueous sodium bicarbonate solution. The reaction mixture was extracted with ethyl acetate. The combined organics were washed with a saturated aqueous sodium chloride solution, dried over sodium sulfate, filtered and concentrated in vacuo. Flash chromatography (30% ethyl acetate/hexane) afforded 4,6-dichloro-l-ethyl-lH-pyrrolo[3,2-c]pyridine (200 mg, 69.6%>). LC- MS calcd. for C₉H₈C1₂N2 [(M)⁺] 214, obsd. 214.9.

Step 2: A microwave reaction vial was charged with 4,6-dichloro-l-ethyl-lH- pyrrolo[3,2-c]pyridine (200 mg, 0.930 mmol), a 2M aqueous sodium hydroxide solution (10 mL) and 1,4-dioxane (3 mL). The vial was sealed and then heated in the microwave at 160°C for 30 min. At this time, the resulting mixture was acidified to pH 6.5 with a 4M aqueous hydrochloric acid solution and then concentrated in vacuo. The residue was diluted with ethanol. The solids were removed by filtration, and the filtrate was concentrated in vacuo. Flash chromatography (10/1 methylene chloride/methanol) afforded 6-chloro-l-ethyl-l ,5-dihydro-pyrrolo[3,2- c]pyridine-4-one (60 mg, 32.8%). LC-MS calcd. for C₉H₉C1N₂0 [(M)⁺] 196, obsd. 196.9.

Intermediate I

3-(4-Bromo-phenyl)-3-methyl-azetidine

Step 1 : To a stirred solution of 2-(4-bromo phenyl) acetonitrile (20 g, 102.04 mmol) in dry tetrahydrofuran (200 mL) was added sodium bis(trimethylsilyl)amide (18.71 g, 102.04 mmol) at 0°C under a nitrogen atmosphere. After stirring for 20 minutes at room temperature, methyl iodide (14.48 g, 102 mmol) was added and then stirred for lh at room temperature. The reaction mixture was quenched with an aqueous ammonium chloride solution and extracted with ethyl acetate (2 x 150 mL). The combined organic layers were washed with water (2 x 100 mL), a saturated aqueous sodium chloride solution (2 x 25 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. Flash chromatography (3-4% ethyl acetate/hexanes) afforded 2-(4-bromo-phenyl)-propionitrile as a light yellow liquid (11.5 g, 53.6%). Step 2: To a stirred solution of 2-(4-bromo-phenyl)-propionitrile (27 g, 128.5 mmol) in pyridine (225 mL) was added paraformaldehyde (15.7 g, 514.3 mmol) and a 40% Triton-B solution (in methanol) (14.4 mL). Then the reaction mixture stirred at room temperature for 16 h. At this time, the reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (300 mL). The organic layer was washed with a 2N aqueous hydrochloric acid solution (2 x 200 mL), water (2 x 100 mL), sodium bicarbonate (2 x 50 mL), a saturated aqueous sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, and concentrated in vacuo. Flash chromatography afforded 2-(4-bromo-phenyl)-3-hydroxy-2-methyl-propionitrile as colorless oil (25.9 g, 84%). Step 3: To a stirred solution of 2-(4-bromo-phenyl)-3-hydroxy-2-methyl-propionitrile (25 g, 104.17 mmol) in pyridine (225 mL) was added /?ara-toluene sulphonyl chloride (29.79 g, 156.25 mmol) and the reaction stirred at room temperature for 16 h. The reaction mixture was diluted with ethyl acetate (300 mL), washed with a 2N aqueous hydrochloric acid solution (2 x 50 mL), water (2 x 100 mL), a saturated aqueous sodium bicarbonate solution (2 x 50 mL), dried over sodium sulfate, and concentrated in vacuo. Flash chromatography (10%> ethyl acetate/hexanes) afforded toluene-4-sulfonic acid 2-(4-bromo-phenyl)-2-cyano-2-methyl-ethyl ester as a colorless liquid (35 g, 73%).

Step 4: To a stirred solution of toluene-4-sulfonic acid 2-(4-bromo-phenyl)-2-cyano-2- methyl-ethyl ester (10 g, 25.38 mmol) in dry tetrahydrofuran (100 mL) was added 1M lithium aluminum hydride (25.3 mL diluted with 25.3 mL of dry tetrahydrofuran) via syringe pump at - 10°C for 1 h and stirring was continued for 30 min at 10 °C. The reaction mixture was quenched with water (1 mL), diluted with tetrahydrofuran (3 mL) followed by a 15% aqueous sodium hydroxide solution (1 mL) and water (3 mL), and filtered through a Celite® pad. The filtrate was concentrated in vacuo. Flash chromatography (8% methanol/methylene chloride) afforded 3-(4- bromo-phenyl)-3-methyl-azetidine as an off-white solid (4.0 g, 70%). ^!H NMR (400 MHz, DMSO- e) δ ppm 1.52 (s, 3 H) 2.42 - 2.57 (m, 1 H) 3.40 (d, J=7.34 Hz, 2 H) 3.72 (d, J=7.34 Hz, 2 H) 7.15 (d, J=8.80 Hz, 2 H) 7.39 - 7.61 (m, 2 H). LC-MS calcd. for Ci₀Hi₂BrN [M⁺] 226, obsd. 226.0/228.2.

Example 1 7-Methyl-2-(4^yridin-4-yl-piperazin-l-yl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one

A solution of 2-chloro-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (Intermediate A) (50.1 mg, 273 μηιοΐ) in ethanol (730 μΐ.) was treated with l-(pyridin-4- yl)piperazine (51.8 mg, 317 μηιοΐ) and N,N-diisopropylethylamine (46.7 mg, 63.10 μΐ., 361 μηιοΐ). The reaction stirred at 100°C overnight. At this time, the reaction was diluted with methanol and methylene chloride and concentrated in vacuo onto Celite®. Flash chromatography (4g silica gel column, 10% methanol/methylene chloride) afforded 7-methyl-2-(4-pyridin-4-yl- piperazin-l-yl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (43 mg, 50.8%) as a white solid. ^!H NMR (300 MHz, DMSO-d₆) δ ppm 3.48 (d, J=4.33 Hz, 4 H) 3.57 (s, 3 H) 3.69 (d, J=6.03 Hz, 4 H) 6.25 (d, J=3.39 Hz, 1 H) 6.78 (d, J=3.20 Hz, 1 H) 6.91 (d, J=6.97 Hz, 2 H) 8.19 (d, J=6.40 Hz, 2 H) 10.90 (s, 1 H). LC-MS calcd. for Ci₆Hi₉N₆0 [(M+H)⁺] 311, obsd. 311.1.

In an analogous manner the following compounds were synthesized following the above procedure:

Example 2 Ethyl 4-(4-(7-methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)piperazin-l- yl)benzoate

From 2-chloro-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (Intermediate A) and ethyl 4-(piperazin-l-yl)benzoate: 4-[4-(7-methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin- 2-yl)-piperazin-l-yl]-benzoic acid ethyl ester was obtained as a white solid (173 mg, 55.2%). 1H NMR (300 MHz, DMSO-d₆) δ ppm 1.21 - 1.37 (m, 3 H) 3.42 (d, J=5.27 Hz, 4 H) 3.57 (s, 3 H) 3.71 (br. s., 4 H) 4.24 (q, J=7.28 Hz, 2 H) 6.25 (d, J=3.39 Hz, 1 H) 6.78 (d, J=3.58 Hz, 1 H) 7.03 (d, J=9.23 Hz, 2 H) 7.80 (d, J=9.04 Hz, 2 H) 10.89 (s, 1 H). LC-MS calcd. for C₂oH24N₅0₃ [(M+H)⁺] 382, obsd. 381.96.

Example 3

2-[4-(4-Chloro-phenyl)^iperazin-l-yl]-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-

From 2-chloro-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (Intermediate A) and l-(4-chlorophenyl)piperazine: 2-[4-(4-chloro-phenyl)-piperazin-l-yl]-7-methyl-3,7-dihydro- pyrrolo[2,3-d]pyrimidin-4-one was obtained as a white solid (34 mg, 35.7%). 1H NMR (300 MHz, DMSO-de) δ ppm 3.22 (d, J=6.03 Hz, 4 H) 3.57 (s, 3 H) 3.69 (s, 4 H) 6.25 (d, J=3.39 Hz, 1 H) 6.78 (d, J=3.20 Hz, 1 H) 7.00 (d, J=9.04 Hz, 2 H) 7.25 (d, J=8.85 Hz, 2 H) 10.87 (s, 1 H). ). LC-MS calcd. for Ci₇Hi₉ClN₅0 [(M+H)⁺] 344, obsd. 343.91.

Example 4

7-Methyl-2-(4^yridin-2-yl^iperazin-l-yl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one

From 2-chloro-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (Intermediate A) and l-(pyridin-2-yl)piperazine: 7-methyl-2-(4-pyridin-2-yl-piperazin-l-yl)-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4-one was obtained as an off-white solid (47 mg, 53.8%). ^!H NMR (300 MHz, DMSO-de) δ ppm 3.57 (s, 7 H) 3.66 (d, J=5.65 Hz, 4 H) 6.25 (d, J=3.39 Hz, 1 H) 6.59 - 6.73 (m, 1 H) 6.77 (d, J=3.20 Hz, 1 H) 6.89 (d, J=8.48 Hz, 1 H) 7.56 (t, J=6.59 Hz, 1 H) 8.14 (d, J=3.39 Hz, 1 H) 10.85 (s, 1 H). LC-MS calcd. for Ci₆Hi₉N₆0 [(M+H)⁺] 311, obsd. 311.1. Example 5

2-[4-(4-Fluoro-2-methanesulfonyl-phenyl)-piperazin-l-yl]-7-methyl-3,7-dihydro- pyrrolo[2,3-d]pyrimidin-4-one

From 2-chloro-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (Intermediate A) and l-(4-fluoro-2-(methylsulfonyl)phenyl)piperazine: 2-[4-(4-fiuoro-2-methanesulfonyl-phenyl)- piperazin-l-yl]-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one was obtained as a light yellow solid (68.8 mg, 60.4%). ^!H NMR (300 MHz, DMSO-d₆) δ ppm 3.03 (br. s., 4 H) 3.46 (s, 3 H) 3.57 (s, 3 H) 3.61 - 3.89 (m, 4 H) 6.26 (d, J=3.39 Hz, 1 H) 6.79 (d, J=3.20 Hz, 1 H) 7.52 - 7.82 (m, 3 H) 10.86 (s, 1 H). LC-MS calcd. for Ci8H₂iFN₅0₃S [(M+H)⁺] 406, obsd. 406.0.

Example 6

7-Methyl-2-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-l-yl]-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4-one

From 2-chloro-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (Intermediate A) and

1 -(3 -(tri fluoromethyl)pyridin-2 -yl)p iperazine : 7 -methyl-2 - [4-(3 -tri fiuoromethyl-pyridin-2 -yl)- piperazin-l-yl]-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one was obtained as a light yellow solid (42.3 mg, 40.7%). ^!H NMR (300 MHz, DMSO-d₆) δ ppm 3.25 (d, J=6.03 Hz, 4 H) 3.55 (s, 3 H) 3.68 (br. s., 4 H) 6.24 (d, J=3.20 Hz, 1 H) 6.77 (d, J=3.58 Hz, 1 H) 7.22 (d, J=7.91 Hz, 1 H) 8.09 (d, J=7.54 Hz, 1 H) 8.53 (s, 1 H) 10.83 (s, 1 H). LC-MS calcd. for Ci₇Hi₈F₃N₆0 [(M+H)⁺] 379, obsd. 379.0. Example 7

2-[4-(3,5-Dichloro-phenyl)-piperazin-l-yl]-7-methyl-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4-one

From 2-chloro-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (Intermediate A) and l-(3,5-dichlorophenyl)piperazine: 2-[4-(3,5-dichloro-phenyl)-piperazin-l-yl]-7-methyl-3,7- dihydro-pyrrolo[2,3-d]pyrimidin-4-one was obtained as a white solid (65.2 mg, 62.9%). ^!H NMR (300 MHz, DMSO- e) δ ppm 3.32 (s, 4 H) 3.57 (s, 3 H) 3.67 (br. s., 4 H) 6.25 (d, J=3.39 Hz, 1 H) 6.78 (d, J=3.20 Hz, 1 H) 6.89 (s, 1 H) 7.00 (d, J=1.70 Hz, 2 H) 10.89 (s, 1 H). LC-MS calcd. for Ci₇Hi₈Cl₂N₅0 [(M+H)⁺] 378, obsd. 378.0.

Example 8

7-Methyl-2-(4^yrimidin-2-yl^iperazin-l-yl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one

From 2-chloro-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (Intermediate A) and 2-(piperazin- 1 -yl)pyrimidine dihydrochloride : 7-methyl-2-(4-pyrimidin-2-yl-piperazin- 1 -yl)-3 ,7- dihydro-pyrrolo[2,3-d]pyrimidin-4-one was obtained as an off-white solid (53.3 mg, 63.4%). 1H NMR (300 MHz, DMSO-d₆) δ ppm 3.57 (s, 3 H) 3.65 (d, J=6.40 Hz, 4 H) 3.77 - 3.86 (m, 4 H) 6.25 (d, J=3.39 Hz, 1 H) 6.67 (t, J=4.71 Hz, 1 H) 6.77 (d, J=3.39 Hz, 1 H) 8.40 (d, J=4.71 Hz, 2 H) 10.83 (s, 1 H). LC-MS calcd. for Ci₅Hi₈N₇0 [(M+H)⁺] 312, obsd. 312.0. Example 9 2-[4-(7-Methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)^iperazin-l-yl]- nicotinonitrile

From 2-chloro-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (Intermediate A) and 2-(piperazin-l-yl)nicotinonitrile: 2-[4-(7-methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin- 2-yl)-piperazin-l-yl]-nicotinonitrile was obtained as a white solid (55.3 mg, 60.9%). ^!H NMR (300 MHz, DMSO- e) δ ppm 3.57 (s, 3 H) 3.71 (s, 8 H) 6.25 (d, J=3.58 Hz, 1 H) 6.78 (d, J=3.39 Hz, 1 H) 6.97 (dd, J=7.72, 4.71 Hz, 1 H) 8.11 (dd, J=7.72, 1.88 Hz, 1 H) 8.44 (dd, J=4.71, 2.07 Hz, 1 H) 10.85 (s, 1 H). LC-MS calcd. for Ci₇Hi₈N₇0 [(M+H)⁺] 336, obsd. 336.0. Example 10

4-(7-Methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)-3,4,5,6-tetrahydro-2H- [l,2']bipyrazinyl-3'-carbonitrile

From 2-chloro-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (Intermediate A) and 3-(piperazin-l-yl)pyrazine-2-carbonitrile: 4-(7-methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3- d]pyrimidin-2-yl)-3,4,5,6-tetrahydro-2H-[l,2']bipyrazinyl-3'-carbonitrile was obtained as an off- white solid (60.7 mg, 66.3%). ^!H NMR (300 MHz, DMSO-d₆) δ ppm 3.57 (s, 3 H) 3.74 (br. s., 4 H) 3.84 (br. s., 4 H) 6.26 (d, J=3.39 Hz, 1 H) 6.78 (d, J=3.39 Hz, 1 H) 8.15 (d, J=2.26 Hz, 1 H) 8.48 (d, J=2.26 Hz, 1 H) 10.85 (s, 1 H). LC-MS calcd. for Ci₆Hi₇N₈0 [(M+H)⁺] 337, obsd. 337.0.

Example 11 7-Methyl-2-(4-methyl-piperazin- 1 -yl)-3 ,7-dihydro-pyrrolo [2 ,3 -d]pyrimidin-4-one

From 2-chloro-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (Intermediate A) and 1-methylpiperazine: 7-methyl-2-(4-methyl-piperazin-l-yl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin- 4-one was obtained as an off-white solid (29.9 mg, 67.9%). ^!H NMR (300 MHz, DMSO-d₆) δ ppm 2.18 (s, 3 H) 2.29 - 2.40 (m, 4 H) 3.46 - 3.58 (m, 7 H) 6.22 (d, J=3.39 Hz, 1 H) 6.74 (d, J=3.39 Hz, 1 H) 10.71 (s, 1 H). LC-MS calcd. for Ci₂Hi₈N₅0 [(M+H)⁺] 248, obsd. 248.2.

Example 12

7-Με^1-2^ο ^1ίη-4^1-3,7-ά^άΓθ-ρ}ττο1ο[2,3-ά]ρ}τ^*^ίάίη-4-οη6

From 2-chloro-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (Intermediate A) and morpholine: 7-methyl-2-mo holin-4-yl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one was obtained as an off-white solid (26.2 mg, 73.9%). 1H NMR (300 MHz, DMSO-d₆) δ ppm 3.53 (d, J=6.78 Hz, 7 H) 3.65 (br. s., 4 H) 6.25 (br. s., 1 H) 6.77 (br. s., 1 H) 10.77 (br. s., 1 H). LC-MS calcd. for C_nHi₅N₄0₂ [(M+H)⁺] 235, obsd. 235.0.

Example 13

2-(4-Methanesulfonyl-piperazin-l-yl)-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4- one

From 2-chloro-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (Intermediate A) and l-(methylsulfonyl)piperazine: 2-(4-methanesulfonyl-piperazin-l-yl)-7-methyl-3,7-dihydro- pyrrolo[2,3-d]pyrimidin-4-one was obtained as a white solid (103.7 mg, 60.2%). ^!H NMR (300 MHz, DMSO- e) δ ppm 2.91 (s, 3 H) 3.13 - 3.24 (m, 4 H) 3.56 (s, 3 H) 3.62 - 3.74 (m, 4 H) 6.25 (d, J=3.39 Hz, 1 H) 6.79 (d, J=3.39 Hz, 1 H) 10.93 (br. s., 1 H). LC-MS calcd. for Ci₂Hi₈N₅0₃S [(M+H)⁺] 312, obsd. 312.0.

Example 14

2-(4-Acetyl-piperazin-l-yl)-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-

From 2-chloro-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (Intermediate A) and l-(piperazin-l-yl)ethanone: 2-(4-acetyl-piperazin-l-yl)-7-methyl-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4-one was obtained as a white solid (53.7 mg, 71.6%). ^!H NMR (300 MHz, DMSO- d₆) δ ppm 2.03 (s, 3 H) 3.44 - 3.70 (m, 11 H) 6.25 (d, J=3.39 Hz, 1 H) 6.77 (d, J=3.39 Hz, 1 H) 10.84 (br. s., 1 H). LC-MS calcd. for Ci₃Hi₈N₅0₂ [(M+H)⁺] 276, obsd. 276.1. Example 15

2- [3 -(4-Bromo-phenyl)-3 -methyl-azetidin- 1 -yl] -7 -methyl-3 ,7-dihydro-pyrrolo [2 ,3 - d]pyrimidin-4-one

From 2-chloro-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (Intermediate A) and 3-(4-bromophenyl)-3-methylazetidine (Intermediate I): 2-[3-(4-bromo-phenyl)-3-methyl- azetidin-l-yl]-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one was obtained as an off-white solid (190.5 mg, 70.3%). 1H NMR (300 MHz, DMSO-d₆) δ ppm 1.59 (s, 3 H) 3.53 (s, 3 H) 4.02 - 4.14 (m, 2 H) 4.15 - 4.28 (m, 2 H) 6.23 (d, J=3.39 Hz, 1 H) 6.73 (d, J=3.58 Hz, 1 H) 7.30 (d, J=8.48 Hz, 2 H) 7.55 (d, J=8.29 Hz, 2 H) 10.91 (s, 1 H). LC-MS calcd. for Ci₇Hi₈BrN₄0 [(M+H)⁺] 373, obsd. 373.0/375.0.

Example 16

7-Methyl-2-(3-phenyl^yrrolidin-l-yl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one

From 2-chloro-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (Intermediate A) and 3 -phenylpyrrolidine : 7-methyl-2-(3 -phenyl-pyrrolidin- 1 -yl)-3 ,7 -dihydro-pyrrolo [2,3- d]pyrimidin-4-one was obtained as a white solid (52.8 mg, 32.1%). ^!H NMR (300 MHz, DMSO- d₆) δ ppm 1.92 - 2.41 (m, 2 H) 3.36 - 3.80 (m, 7 H) 3.91 - 4.05 (m, 1 H) 6.22 (d, J=3.39 Hz, 1 H) 6.69 (d, J=3.58 Hz, 1 H) 7.17 - 7.39 (m, 5 H) 10.42 (s, 1 H). LC-MS calcd. for Ci₇Hi₉N₄0 [(M+H)⁺] 295, obsd. 295.1.

Example 17

2-[4-(4-Fluoro-phenyl)-piperazin-l-yl]-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-

From 2-chloro-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (Intermediate A) and l-(4-fluorophenyl)piperazine: 2-[4-(4-fluoro-phenyl)-piperazin-l-yl]-7-methyl-3,7-dihydro- pyrrolo[2,3-d]pyrimidin-4-one was obtained as a white solid (55.6 mg, 60.5%). ^!H NMR (300 MHz, DMSO- e) δ ppm 3.08 - 3.22 (m, 4 H) 3.57 (s, 3 H) 3.69 (d, J=5.46 Hz, 4 H) 6.25 (d, J=3.39 Hz, 1 H) 6.78 (d, J=3.20 Hz, 1 H) 6.93 - 7.19 (m, 4 H) 10.87 (s, 1 H). LC-MS calcd. for Ci₇Hi₉FN₅0 [(M+H)⁺] 328, obsd. 328.1.

Example 18 2 - [4 -(3 -Fluoro-phenyl) ^ ip erazin- 1 -yl] -7

From 2-chloro-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (Intermediate A) and l-(3-fluorophenyl)piperazine: 2-[4-(3-fluoro-phenyl)-piperazin-l-yl]-7-methyl-3,7-dihydro- pyrrolo[2,3-d]pyrimidin-4-one was obtained as an off-white solid (34.1 mg, 64.6%). 1H NMR (300 MHz, DMSO- e) δ ppm 3.20 - 3.30 (m, 4 H) 3.57 (s, 3 H) 3.70 (d, J=4.90 Hz, 4 H) 6.25 (d, J=3.39 Hz, 1 H) 6.48 - 6.66 (m, 1 H) 6.70 - 6.93 (m, 3 H) 7.12 - 7.35 (m, 1 H) 10.88 (s, 1 H). LC-MS calcd. for Ci₇Hi₉FN₅0 [(M+H)⁺] 328, obsd. 327.85. Example 19

2-[4-(7-Methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)-piperazin-l-yl]- benzonitrile

From 2-chloro-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (Intermediate A) and 2-(piperazin-l-yl)benzonitrile: 2-[4-(7-methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2- yl)-piperazin-l-yl]-benzonitrile was obtained as a white solid (55.6 mg, 61.3%). ^!H NMR (300 MHz, DMSO-de) δ ppm 3.23 (br. s., 4 H) 3.58 (s, 3 H) 3.75 (br. s., 4 H) 6.26 (d, J=3.20 Hz, 1 H) 6.78 (d, J=3.58 Hz, 1 H) 7.13 (t, J=7.54 Hz, 1 H) 7.22 (d, J=8.29 Hz, 1 H) 7.62 (t, J=7.25 Hz, 1 H) 7.74 (d, J=7.72 Hz, 1 H) 10.88 (s, 1 H). LC-MS calcd. for Ci₈Hi₉N₆0 [(M+H)⁺] 335, obsd. 335.0.

Example 20 2-[4-(2,4-Difluoro-phenyl)-piperazin-l-yl]-7-methyl-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4-one

From 2-chloro-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (Intermediate A) and l-(2,4-difluorophenyl)piperazine: 2-[4-(2,4-difluoro-phenyl)-piperazin-l-yl]-7-methyl-3,7- dihydro-pyrrolo[2,3-d]pyrimidin-4-one was obtained as a white solid (43.4 mg, 46.3%). ^!H NMR (300 MHz, DMSO- e) δ ppm 2.94 - 3.10 (m, 4 H) 3.56 (s, 3 H) 3.70 (d, J=4.52 Hz, 4 H) 6.25 (d, J=3.39 Hz, 1 H) 6.78 (d, J=3.39 Hz, 1 H) 6.93 - 7.31 (m, 3 H) 10.85 (s, 1 H). LC-MS calcd. for Ci₇Hi₈F₂N₅0 [(M+H)⁺] 346, obsd. 346.0.

Example 21

3-[4-(7-Methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)-piperazin-l-yl]- benzonitrile

From 2-chloro-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (Intermediate A) and 3-(piperazin-l-yl)benzonitrile: 3-[4-(7-methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2- yl)-piperazin-l-yl]-benzonitrile was obtained as a white solid (47.4 mg, 51.9%). ^!H NMR (300 MHz, DMSO-de) δ ppm 2.50 (br. s, 4 H) 2.75 (s, 3 H) 2.89 (br. s., 4 H) 5.44 (d, J=3.20 Hz, 1 H) 5.96 (d, J=3.20 Hz, 1 H) 6.37 (d, J=7.16 Hz, 1 H) 6.47 - 6.64 (m, 3 H) 10.07 (s, 1 H). LC-MS calcd. for Ci₈Hi₉N₆0 [(M+H)⁺] 335, obsd. 335.0.

Example 22 4-[4-(7-Methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)-piperazin-l-yl]- benzonitrile

From 2-chloro-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (Intermediate A) and 4-(piperazin-l-yl)benzonitrile: 4-[4-(7-methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2- yl)-piperazin-l-yl]-benzonitrile was obtained as a white solid (47.4 mg, 52.1%). ^!H NMR (300 MHz, DMSO- e) δ ppm 3.40 - 3.51 (m, 4 H) 3.57 (s, 3 H) 3.70 (d, J=5.46 Hz, 4 H) 6.25 (d, J=3.39 Hz, 1 H) 6.78 (d, J=3.39 Hz, 1 H) 7.07 (d, J=9.04 Hz, 2 H) 7.61 (d, J=9.04 Hz, 2 H) 10.88 (s, 1 H). LC-MS calcd. for Ci₈Hi₉N₆0 [(M+H)⁺] 335, obsd. 335.0.

Example 23

7-Methyl-2-[4-(2-trifluoromethyl-phenyl)-piperazin-l-yl]-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4-one

From 2-chloro-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (Intermediate A) and l-(2-(trifluoromethyl)phenyl)piperazine: 7-methyl-2-[4-(2-trifluoromethyl-phenyl)-piperazin-l- yl]-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one was obtained as a white solid (33.5 mg, 54.5%). ^!H NMR (300 MHz, DMSO-d₆) δ ppm 2.85 - 2.99 (m, 4 H) 3.56 (s, 3 H) 3.68 (br. s., 4 H) 6.25 (d, J=3.39 Hz, 1 H) 6.78 (d, J=3.58 Hz, 1 H) 7.37 (t, J=7.16 Hz, 1 H) 7.54 - 7.77 (m, 3 H) 10.83 (s, 1 H). LC-MS calcd. for Ci₈Hi₉F₃N₅0 [(M+H)⁺] 378, obsd. 378.1.

Example 24 2-[4-(2-Fluoro-4-methanesulfonyl-phenyl)-piperazin-l-yl]-7-methyl-3,7-dihydro- pyrrolo[2,3-d]pyrimidin-4-one

From 2-chloro-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (Intermediate A) and 1 -(2-fluoro-4-(methylsulfonyl)phenyl)piperazine: 2-[4-(2-fluoro-4-methanesulfonyl-phenyl)- piperazin-l-yl]-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one was obtained as a white solid (33.4 mg, 49.6%). ^!H NMR (300 MHz, DMSO-d₆) δ ppm 3.20 (s, 3 H) 3.27 (br. s., 4 H) 3.57 (s, 3 H) 3.73 (br. s., 4 H) 6.26 (d, J=3.39 Hz, 1 H) 6.79 (d, J=3.01 Hz, 1 H) 7.27 (t, J=8.67 Hz, 1 H) 7.58 - 7.78 (m, 2 H) 10.89 (s, 1 H). LC-MS calcd. for Ci8H₂iFN₅0₃S [(M+H)⁺] 406, obsd. 406.0.

Example 25

7-Methyl-2-[4-(4^rifluoromethyl-pyridin-2-yl)-piperazin-l-yl]-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4-one

1 -(4 -(tri fluoromethyl)pyridin-2 -yl)p iperazine : 7 -methyl-2 - [4-(4-tri fiuoromethyl-pyridin-2 -yl)- piperazin-l-yl]-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one was obtained as a white solid (26.3 mg, 42.1%). ^!H NMR (300 MHz, DMSO-d₆) δ ppm 3.57 (s, 3 H) 3.71 (d, J=7.91 Hz, 8 H) 6.25 (d, J=3.39 Hz, 1 H) 6.78 (d, J=3.39 Hz, 1 H) 7.02 (d, J=9.23 Hz, 1 H) 7.83 (d, J=11.68 Hz, 1 H) 8.44 (s, 1 H) 10.87 (br. s., 1 H). LC-MS calcd. for Ci₇Hi₈F₃N₆0 [(M+H)⁺] 379, obsd. 379.1.

Example 26 2-[4-(3 ,4-Dichloro-phenyl)-piperazin- 1 -yl]-7-methyl-3 ,7-dihydro-pyrrolo [2 ,3 - d]pyrimidin-4-one

From 2-chloro-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (Intermediate A) and 1 -(3 ,4-dichlorophenyl)piperazine: 2-[4-(3 ,4-dichloro-phenyl)-piperazin-l -yl]-7-methyl-3,7- dihydro-pyrrolo[2,3-d]pyrimidin-4-one was obtained as a white solid (28.5 mg, 44.9%). ^!H NMR (300 MHz, DMSO- e) δ ppm 3.28 (br. s., 4 H) 3.57 (s, 3 H) 3.68 (br. s., 4 H) 6.25 (d, J=3.39 Hz, 1 H) 6.78 (d, J=3.39 Hz, 1 H) 7.00 (d, J=8.85 Hz, 1 H) 7.20 (d, J=2.83 Hz, 1 H) 7.42 (d, J=8.85 Hz, 1 H) 10.89 (s, 1 H). LC-MS calcd. for Ci₇Hi₈Cl₂N₅0 [(M+H)⁺] 378, obsd. 378.0. Example 27

7-But-3-enyl-2-[4-(2-chloro-phenyl)-piperazin-l-yl]-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4-one

From 7-but-3-enyl-2-chloro-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (Intermediate B) and l-(2-chlorophenyl)piperazine dihydrochloride: 7-but-3-enyl-2-[4-(2-chloro-phenyl)- piperazin-l-yl]-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one was obtained as a light yellow solid (275.2 mg, 87.0%). 1H NMR (300 MHz, DMSO-d₆) δ ppm 2.42 - 2.58 (m, 2 H) 3.05 (br. s., 4 H) 3.71 (br. s., 4 H) 4.05 (t, J=6.97 Hz, 2 H) 4.91 - 5.13 (m, 2 H) 5.65 - 5.89 (m, 1 H) 6.24 (d, J=3.39 Hz, 1 H) 6.83 (d, J=3.39 Hz, 1 H) 7.07 (t, J=6.88 Hz, 1 H) 7.15 - 7.24 (m, 1 H) 7.26 - 7.37 (m, 1 H) 7.44 (dd, J=7.82, 1.41 Hz, 1 H) 10.85 (s, 1 H). LC-MS calcd. for C₂oH₂₃ClN₅0 [(M+H)⁺] 384, obsd. 383.9.

Example 28 2-[4-(2-Fluoro-phenyl)^iperazin-l-yl]-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-

From 2-chloro-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (Intermediate A) and 1 -(2-fluorophenyl)piperazine: 2-[4-(2-fluoro-phenyl)-piperazin- 1 -yl]-7-methyl-3,7-dihydro- pyrrolo[2,3-d]pyrimidin-4-one was obtained as a white solid (38.4 mg, 67.3%). ^!H NMR (400 MHz, DMSO- e) δ ppm 3.01 - 3.14 (m, 4 H) 3.57 (s, 3 H) 3.62 - 3.84 (m, 4 H) 6.25 (d, J=3.52 Hz, 1 H) 6.78 (d, J=3.52 Hz, 1 H) 6.90 - 7.28 (m, 4 H) 10.85 (s, 1 H). LC-MS calcd. for Ci₇Hi₉FN₅0 [(M+H)⁺] 328, obsd. 327.9. Example 29

7-Methyl-2-(4-phenyl-piperazin-l-yl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one

From 2-chloro-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (Intermediate A) and 1- phenylpiperazine: 7-methyl-2-(4-phenyl-piperazin-l-yl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4- one was obtained as a light yellow solid (30 mg, 59.3%). ^!H NMR (400 MHz, DMSO-d₆) δ ppm 3.13 - 3.27 (m, 4 H) 3.57 (s, 3 H) 3.62 - 3.78 (m, 4 H) 6.25 (d, J=3.13 Hz,

1 H) 6.68 - 6.88 (m, 2 H) 6.99 (d, J=7.81 Hz, 2 H) 7.16 - 7.31 (m, 2 H) 10.87 (s, 1 H). LC-MS calcd. for Ci₇H₂₀N₅O [(M+H)⁺] 310, obsd. 310.1.

Example 30 2-[4-(2-Chloro-phenyl)-piperazin-l-yl]-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4- one

From 2-chloro-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (Intermediate A) and l-(2-chlorophenyl)piperazine dihydrochloride salt: 2-[4-(2-chloro-phenyl)-piperazin-l-yl]-7- methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one was obtained as a white solid (13.3 mg, 23.7%). ^!H NMR (400 MHz, DMSO-d₆) δ ppm 2.96 - 3.13 (m, 4 H) 3.57 (s, 3 H) 3.65 - 3.78 (m, 4 H) 6.25 (d, J=3.52 Hz, 1 H) 6.78 (d, J=3.52 Hz, 1 H) 7.07 (td, J=7.62, 1.56 Hz, 1 H)

7.20 (dd, J=7.81, 1.56 Hz, 1 H) 7.26 - 7.36 (m, 1 H) 7.44 (dd, J=8.01 , 1.37 Hz, 1 H) 10.85 (s, 1 H). LC-MS calcd. for Ci₇Hi₉ClN₅0 [(M+H)⁺] 344, obsd. 344.1.

Example 31 7-Methyl-2-(2,3,5,6-tetrahydro-[l ,2']bipyrazinyl-4-yl)-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4-one

From 2-chloro-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (Intermediate A) and l-(2-pyrazinyl)-piperazine: 7-methyl-2-(2,3,5,6-tetrahydro-[l,2']bipyrazinyl-4-yl)-3,7-dihydro- pyrrolo[2,3-d]pyrimidin-4-one was obtained as an off-white solid (37 mg, 72.7%). ^!H NMR (300 MHz, DMSO-de) δ ppm 3.57 (s, 3 H) 3.68 (br. s., 8 H) 6.25 (d, J=3.39 Hz, 1 H) 6.78 (d, J=3.20 Hz, 1 H) 7.87 (d, J=2.64 Hz, 1 H) 8.11 (s, 1 H) 8.38 (d, J=1.32 Hz, 1 H) 10.88 (s, 1 H). LC-MS calcd. for Ci₅Hi₈N₇0 [(M+H)⁺] 312, obsd. 312.1.

Example 32

6-[4-(7-Methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)-piperazin-l-yl]- nicotinonitrile

From 2-chloro-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (Intermediate A) and 6-piperazinonicotinonitrile: 6-[4-(7-methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2- yl)-piperazin-l-yl]-nicotinonitrile was obtained as a white solid (36.2 mg, 66.1%). ^!H NMR (300 MHz, DMSO- e) δ ppm 3.57 (s, 3 H) 3.67 (br. s., 4 H) 3.75 (br. s., 4 H) 6.25 (d, J=3.39 Hz, 1 H) 6.78 (d, J=3.20 Hz, 1 H) 6.99 (d, J=8.67 Hz, 1 H) 7.77 - 7.98 (m, 1 H) 8.51 (s, 1 H) 10.86 (s, 1 H). LC-MS calcd. for Ci₇Hi₈N₇0 [(M+H)⁺] 336, obsd. 336.1.

Example 33

2-[(lS,4S)-5-(3-Fluoro-phenyl)-2,5-diaza-bicyclo[2.2.1]hept-2-yl]-7-methyl-3,7-dihydro- pyrrolo[2,3-d]pyrimidin-4-one

From 2-chloro-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (Intermediate A) and (lS,4S)-2-(3-fluorophenyl)-2,5-diazabicyclo[2.2.1]heptane: 2-[(lS,4S)-5-(3-fluoro-phenyl)-2,5- diaza-bicyclo[2.2.1 ]hept-2-yl]-7-methyl-3 ,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one was obtained as an off-white solid (29.3 mg, 52.8%). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.93 - 2.09 (m, 2 H) 3.08 (d, J=9.37 Hz, 1 H) 3.40 - 3.48 (m, 1 H) 3.50 (s, 3 H) 3.52 - 3.62 (m, 2 H) 4.65 (s, 1 H) 5.02 (s, 1 H) 6.19 (d, J=3.52 Hz, 1 H) 6.26 - 6.55 (m, 3 H) 6.68 (d, J=3.52 Hz, 1 H) 7.13 (q, J=7.94 Hz, 1 H) 10.62 (br. s., 1 H). LC-MS calcd. for Ci₈Hi₉FN₅0 [(M+H)⁺] 340, obsd. 340.1.

Example 34 2-[4-(3,5-Dichloro-pyridin-4-yl)^iperazin-l-yl]-7-methyl-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4-one

From 2-chloro-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (Intermediate A) and l-(3,5-dichloro-4-pyridyl)piperazine: 2-[4-(3,5-dichloro-pyridin-4-yl)-piperazin-l-yl]-7-methyl- 3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one was obtained as an off-white solid (40.8 mg, 62.1%). ^!H NMR (400 MHz, DMSO-d₆) δ ppm 3.34 - 3.41 (m, 4 H) 3.57 (s, 3 H) 3.71 (br. s., 4 H) 6.27 (d, J=3.52 Hz, 1 H) 6.79 (d, J=3.52 Hz, 1 H) 8.49 (s, 2 H) 10.90 (s, 1 H). LC-MS calcd. for CieHnCbNeO [(M+H)⁺] 379, obsd. 379.0. Example 35

6-[4-(2-Fluoro-phenyl)-piperazin-l -yl]- 1 -methyl- 1 ,5-dihydro-pyrrolo[3,2-c]pyridin-4-one

A mixture of 6-chloro-l-methyl-l,5-dihydro-pyrrolo[3,2-c]pyridine-4-one (Intermediate

G) (17 mg, 0.09 mmol) and l-(2-fluorophenyl)piperazine (140 mg, 0.77 mmol) was heated at 140°C in a sealed tube overnight. Flash chromatography (20/1 methylene chloride/methanol) afforded 6-[4-(2-fiuoro-phenyl)-piperazin-l-yl]-l-methyl-l,5-dihydro-pyrrolo[3,2-c]pyridin-4- one (20 mg, 65.8%) as a white solid. ^!H NMR (400 MHz, DMSO-d₆) δ ppm 3.1 (d, J=4.77 Hz, 4

H) 3.2 - 3.3 (m, 4 H) 3.6 (s, 3 H) 5.8 (s, 1 H) 6.3 (d, J=3.01 Hz, 1 H) 6.9 (d, J=3.01 Hz, 1 H) 7.0 - 7.0 (m, 1 H) 7.1 - 7.2 (m, 3 H) 10.6 (s, 1 H). LC-MS calcd. for Ci8H₂oFN₄0 [(M+H)⁺] 327, obsd. 327.1.

Example 36 1 -Ethyl-6-[4-(2-fluoro-phenyl)-piperazin- 1 -yl]- 1 ,5-dihydro-pyrrolo[3,2-c]pyridin-4-one

A mixture of 6-chloro-l-ethyl-l,5-dihydro-pyrrolo[3,2-c]pyridine-4-one (Intermediate G) (16 mg, 0.081 mmol) and l-(2-fluorophenyl)piperazine (160 mg, 0.888 mmol) was heated at 140°C in a sealed tube for 5 h. Flash chromatography (20/1 methylene chloride/methanol) afforded 1 -ethyl-6-[4-(2-fluoro-phenyl)-piperazin- 1 -yl]- 1 ,5-dihydro-pyrrolo[3 ,2-c]pyridin-4-one (18 mg, 65%) as a white solid. 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.3 (t, J=7.28 Hz, 3 H) 3.1 (d, J=4.77 Hz, 4 H) 3.2 (d, J=4.77 Hz, 4 H) 4.0 (q, J=7.19 Hz, 2 H) 5.8 (s, 1 H) 6.3 (d, J=3.01 Hz, 1 H) 6.9 (d, J=3.01 Hz, 1 H) 7.1 - 7.2 (m, 3 H) 10.6 (s, 1 H). LC-MS calcd. for C₁₉H₂₂FN₄O [(M+H)⁺] 341, obsd. 341.1.

Example 37

2-(4-Trifiuoromethyl-phenyl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one

A microwave reaction vial was charged with 2-chloro-3 ,7-dihydro-pyrrolo[2,3- d]pyrimidin-4-one (Intermediate F) (80 mg, 0.32 mmol), 4,4,5 ,5-tetramethyl-2-(4- (trifluoromethyl)phenyl)-l,3,2-dioxaborolane (154 mg, 0.56 mmol), tetrakis (triphenylphosphine)palladium(O) (27.3 mg, 0.024 mmol) and a 2M aqueous sodium carbonate solution (0.75 mL) in ethanol (3 mL). The vial was sealed and the reaction was heated in the microwave at 150°C for 10 min. At this time, the resulting mixture was filtered through a pad of Celite® and concentrated in vacuo. Flash chromatography (30/1 methylene chloride/methanol) afforded 2-(4-trifluoromethyl-phenyl)-3 ,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (5.0 mg, 3.8%) as a white solid. 'HNMR (400 MHz, DMSO-d₆) δ ppm 6.50 - 6.59 (m, 1 H) 7.9 (d, 2 H) 7.1 1 - 7.19 (m, 1 H) 8.3 (d, 2 H) 12.1 (s, 1 H) 12.3 (s, 1 H). LC-MS calcd. for C₁₃H₉F₃N₃O [(M+H)⁺] 280, obsd. 279.9. Example 38

7-Methyl-2-(4 rifluoromethyl^henyl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one

A microwave reaction vial was charged with 2-chloro-7-methyl-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4-one (Intermediate A) (60 mg, 0.32 mmol), 4,4,5,5-tetramethyl-2-(4- (trifluoromethyl)phenyl)-l,3,2-dioxaborolane (107 mg, 0.39 mmol), tetrakis(triphenylphosphine)palladium(0) (18.9 mg, 0.01 mmol), and a 2M aqueous sodium carbonate solution (0.49 mL) in ethanol (2 mL). The vial was capped and heated in the microwave at 150°C for 8 min. The resulting mixture was filtered through a pad of Celite® and concentrated in vacuo. Flash chromatography (30/1 methylene chloride/methanol) afforded 7- methyl-2-(4-trifluoromethyl-phenyl)-3,7-dihydro-pyrrolo[2,3,-d]pyrimidin-4-one (29 mg, 30%) as a white solid. LC-MS calcd. for C14H11F3N3O [(M+H)⁺] 294, obsd. 294.0.

In an analogous manner the following compounds were synthesized following the above procedure: Example 39

2-(4-Methoxy-phenyl)-7-methyl-3 ,7-dihydro-pyrrolo [2 ,3 -d]pyrimidin-4-one

From 2-chloro-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (Intermediate A) and 4-methoxyphenylboronic acid: 2-(4-methoxy-phenyl)-7-methyl-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4-one was obtained as a white solid. LC-MS calcd. for C14H14N3O2 [(M+H)⁺] 256, obsd. 256.0.

Example 40 2-(6-Ethoxy-pyridin-3-yl)-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one

From 2-chloro-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (Intermediate A) and 2-ethoxy-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine: 2-(6-ethoxy-pyridin-3-yl)-7- methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one was obtained as a white solid (10 mg, 13.6%). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.3 (t, J=7.15 Hz, 3 H) 3.8 (s, 3 H) 4.4 (q, J=7.03 Hz, 2 H) 6.5 (d, J=3.51 Hz, 1 H) 6.9 (d, J=8.78 Hz, 1 H) 7.1 (d, J=3.26 Hz, 1 H) 8.4 (dd, J=8.78, 2.51 Hz, 1 H) 8.9 (d, J=2.51 Hz, 1 H) 12.1 (br. s., 1 H). LC-MS calcd. for Ci₄Hi₅N₄02 [(M+H)⁺] 271, obsd. 271.0.

Example 41

7-Methyl-2-pyridin-3-yl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-

From 2-chloro-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (Intermediate A) and 3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine: 7-methyl-2-pyridin-3-yl-3,7-dihydro- pyrrolo[2,3-d]pyrimidin-4-one was obtained as a white solid (57 mg, 80.2%). 1H NMR (400 MHz, DMSO-de) δ ppm 3.79 (s, 3 H) 6.52 (d, J=3.26 Hz, 1 H) 7.18 (d, J=3.26 Hz, 1 H) 7.56 (dd, J=8.03, 4.77 Hz, 1 H) 8.47 (dt, J=8.16, 1.82 Hz, 1 H) 8.71 (dd, J=4.77, 1.51 Hz, 1 H) 9.29 (d, J=1.76 Hz, 1 H) 12.31 (br. s., 1 H). LC-MS calcd. for Ci₂HnN₄0 [(M+H)⁺] 227, obsd. 227.0.

Example 42

7-Methyl-2-(6-methyl-pyridin-3-yl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one

From 2-chloro-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (Intermediate A) and 2-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine: 7-methyl-2-(6-methyl- pyridin-3-yl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one was obtained as a white solid (45 mg, 59.6%). ^!H NMR (400 MHz, DMSO-d₆) δ ppm 2.5 (s, 3 H) 3.8 (s, 3 H) 6.5 (d, J=3.26 Hz, 1 H) 7.2 (d, J=3.26 Hz, 1 H) 7.4 (d, J=8.28 Hz, 1 H) 8.4 (dd, J=8.16, 2.38 Hz, 1 H) 9.2 (d, J=2.01 Hz, 1 H) 12.2 (br. s., 1 H). LC-MS calcd. for C13H13N4O [(M+H)⁺] 241, obsd. 241.0.

Example 43

4-(7-Methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)-benzonitrile

From 2-chloro-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (Intermediate A) and 4-cyanophenylboronic acid: 4-(7-methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)- benzonitrile was obtained as a white solid. LC-MS calcd. for Ci₄HnN₄0 [(M+H)⁺] 251 , obsd. 250.9. Example 44

7-Methyl-2-(6-trifluoromethyl^yridin-3-yl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one

A high pressure microwave reaction vial was charged with 2-chloro-7-methyl-3,7 dihydro-pyrrolo[2,3-d]pyrimidin-4-one (Intermediate A) (55 mg, 0.3 mmol), 6 (trifluoromethyl)pyridin-3-ylboronic acid (68.6 mg, 0.36 mmol), [1 ,1 ' bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (21.9 mg, 0.03 mmol), a 2M aqueous sodium carbonate solution (0.45 mL, 0.9 mmol), and ethanol (2 mL). The vessel was sealed, degassed and flushed with nitrogen three times. The reaction was then heated at 150°C for 10 min in a Biotage microwave reactor. At this time, the resulting black mixture was concentrated in vacuo. The residue was treated with ethyl acetate (20 mL), stirred and filtered. The filtrate was concentrated in vacuo. Reverse phase chromatography (10-100% acetonitrile/water) and lyophilization afforded 7-methyl-2-(6-trifluoromethyl-pyridin-3-yl)-3, 7- dihydro-pyrrolo [2, 3-d] pyrimidin-4-one (6 mg, 6.81%) as a white solid. LC-MS calcd. for C13H10F3N4O [(M+H)⁺] 295, obsd. 294.8. Example 45 l-Methyl-6-(4-trifluoromethyl-phenyl)-l,5-dihydro-pyrrolo[3,2-c]pyridin

A microwave reaction vial was charged with 6-chloro-l-methyl-l ,5-dihydro-pyrrolo[3,2- c]pyridine-4-one (Intermediate G) (16 mg, 0.08 mmol), 4-(trifluoromethyl)phenylboronic acid (20 mg, 0.10 mmol), tetrakis(triphenylphosphine)palladium(0) (5.06 mg, 0.004 mmol), and 2M aqueous sodium carbonate solution (0.13 mL) in ethanol (2 mL). The vial was sealed and then heated in a microwave at 140°C for 10 min. At this time, the resulting mixture was filtered through a pad of Celite® and concentrated in vacuo. Flash chromatography (20/1 methylene chloride/methanol) afforded 1 -methyl-6-(4-trifluoromethyl-phenyl)- 1 ,5 -dihydro-pyrrolo [3 ,2- c]pyridin-4-one (25.6 mg, 39.1%) as a white solid. ^!H NMR (400 MHz, DMSO-d₆) δ ppm 3.8 (s, 3 H) 6.5 (d, J=3.01 Hz, 1 H) 7.0 (s, 1 H) 7.1 (d, J=3.01 Hz, 1 H) 7.8 (d, J=8.28 Hz, 2 H) 8.0 (d, J=8.28 Hz, 2 H) 11.1 (br. s., 1 H). LC-MS calcd. for C15H12F3N2O [(M+H)⁺] 293, obsd. 293.0.

In an analogous manner the following compounds were synthesized following the above procedure: Example 46 l-Ethyl-6-(4-trifluoromethyl-phenyl)-l,5-dihydro-pyrrolo[3,2-c]pyridin-4-one

From 6-chloro-l-ethyl-l ,5-dihydro-pyrrolo[3,2-c]pyridine-4-one (40 mg, 0.203 mmol) (Intermediate H) and 4-(trifluoromethyl)phenylboronic acid (46.4 mg, 0.244 mmol): l-ethyl-6- (4-trifluoromethyl-phenyl)-l ,5-dihydro-pyrrolo[3,2-c]pyridin-4-one was obtained as a white solid (49 mg, 78.6%). ^!H NMR (400 MHz, DMSO-d₆) δ ppm 1.35 (t, J=7.15 Hz, 3 H) 4.20 (q, J=7.28 Hz, 2 H) 6.55 (d, J=3.01 Hz, 1 H) 7.06 (s, 1 H) 7.22 (d, J=3.01 Hz, 1 H) 7.81 (d, J=8.53 Hz, 2 H) 8.00 (d, J=8.28 Hz, 2 H) 11.14 (s, 1 H). LC-MS calcd. for C16H13F3N2O [(M)⁺] 306, obsd. 306.8.

Example 47

1 -Methyl-6-(l -methyl- lH-pyrazol-4-yl)- 1 ,5 -dihydro-pyrrolo [3 ,2-c]pyridin-4-one

From 6-chloro-l-methyl-l ,5-dihydro-pyrrolo[3,2-c]pyridine-4-one (Intermediate G) and l-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole: 2-(4-methoxy-phenyl)-7- methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one was obtained as a white solid (21 mg, 56%>). 1H NMR (400 MHz, DMSO-d₆) δ ppm 3.72 (s, 3 H) 3.86 (s, 3 H) 6.46 (dd, J=3.01, 0.75 Hz, 1 H) 6.83 (s, 1 H) 7.03 (d, J=3.01 Hz, 1 H) 8.04 (d, J=0.75 Hz, 1 H) 8.30 (s, 1 H) 10.86 (s, 1 H). LC- MS calcd. for C12H13N4O [(M+H)⁺] 229, obsd. 229.0.

Example 48

2-[4-(4-Fluoro-phenyl)-piperidin-l-yl]-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4- one

A microwave reaction vial was charged with 2-chloro-7-methyl-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4-one (Intermediate A) (25 mg, 0.13 mmol), 4-(4-fiuorophenyl)piperidine hydrochloride (35.2 mg, 0.16 mmol), and N,N-diisopropylethylamine (52.8 mg, 0.41 mmol) in ethanol (1.5 mL). The vial was sealed and then heated in the microwave at 140°C for 15 min. At this time, the resulting mixture was concentrated in vacuo. Flash chromatography (20/1 methylene chloride/methanol) afforded 2-[4-(4-fluoro-phenyl)-piperidin-l-yl]-7-methyl-3,7- dihydro-pyrrolo[2,3-d]pyrimidin-4-one (44.4 mg, 36%) as a white solid. ^!H NMR (400 MHz, DMSO- e) δ ppm 1.5 - 1.7 (m, 2 H) 1.8 (d, J=11.55 Hz, 2 H) 2.8 (br. s., 1 H) 2.9 (t, J=12.05 Hz, 2 H) 3.5 (s, 3 H) 4.5 (d, J=13.05 Hz, 2 H) 6.2 (d, J=3.51 Hz, 1 H) 6.7 (d, J=3.26 Hz, 1 H) 7.1 (t, J=8.78 Hz, 2 H) 7.3 (dd, J=8.53, 5.52 Hz, 2 H) 10.7 (s, 1 H). LC-MS calcd. for Ci₈H₂oFN₄0 [(M+H)⁺] 327, obsd. 327.0.

Example 49

7-But-3-enyl-2-(4-trifluoromethyl-phenyl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one

A microwave reaction vial was charged with 7-but-3-enyl-2-chloro-3,7-dihydro- pyrrolo[2,3-d]pyrimidin-4-one (Intermediate B) (96.1 mg, 430 μηιοΐ,), ethanol (1.6 mL), a 2M aqueous sodium carbonate solution (645 μί, 1.29 mmol), 4-(trifiuoromethyl)phenylboronic acid (98.2 mg, 517 μηιοΐ), and tetrakis(triphenylphosphine)palladium(0) (27.2 mg, 23.5 μηιοΐ). The reaction was heated in a microwave at 150°C for 68 min. The reaction was filtered through a pad of Celite®, rinsing with ethanol. The filtrate was concentrated in vacuo onto Celite®. Flash chromatography (12 g silica gel column, 10-30% ethyl acetate/hexanes) afforded 7-but-3-enyl-2- (4-trifluoromethyl-phenyl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (98.9 mg, 69.1%) as an off-white solid. ^!H NMR (300 MHz, DMSO-d₆) δ ppm 2.59 (q, J=6.66 Hz, 2 H) 4.29 (t, J=6.88 Hz, 2 H) 4.84 - 5.21 (m, 2 H) 5.58 - 5.95 (m, 1 H) 6.52 (d, J=3.20 Hz, 1 H) 7.25 (d, J=3.20 Hz, 1 H) 7.90 (d, J=8.29 Hz, 2 H) 8.34 (d, J=7.91 Hz, 2 H) 12.32 (s, 1 H). LC-MS calcd. for Ci₇Hi₅F₃N30 [(M+H)⁺] 334, obsd. 334.1.

Example 50

7-Ethyl-2-(4-trifiuoromethyl-phenyl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one

From 2-chloro-7-ethyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (Intermediate C) and 4-(trifluoromethyl)phenylboronic acid: 7-ethyl-2-(4-trifiuoromethyl-phenyl)-3,7-dihydro- pyrrolo[2,3-d]pyrimidin-4-one was obtained as a white solid (51.3 mg, 73.3%). ^!H NMR (300 MHz, DMSO-de) δ ppm 1.40 (t, J=7.35 Hz, 3 H) 4.24 (q, J=6.84 Hz, 2 H) 6.53 (d, J=3.58 Hz, 1 H) 7.26 (d, .7=3.01 Hz, 1 H) 7.90 (d, J=7.91 Hz, 2 H) 8.34 (d, .7=7.91 Hz, 2 H) 12.31 (br. s., 1 H). LC-MS calcd. for Ci₅Hi₃F₃N₃0 [(M+H)⁺] 308, obsd. 307.9. Example 51

7-Propyl-2-(4-trifluoromethyl-phenyl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one

From 2-chloro-7-propyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (Intermediate D) and 4-(trifluoromethyl)phenylboronic acid: 7-propyl-2-(4-trifiuoromethyl-phenyl)-3 ,7-dihydro- pyrrolo[2,3-d]pyrimidin-4-one was obtained as a light yellow solid (46.5 mg, 61.3%). ^!H NMR (400 MHz, DMSO-de) δ ppm 0.85 (t, J=7.42 Hz, 3 H) 1.82 (sxt, J=7.27 Hz, 2 H) 4.17 (t, J=7.03 Hz, 2 H) 6.54 (d, .7=3.13 Hz, 1 H) 7.25 (d, J=3.52 Hz, 1 H) 7.90 (d, J=8.59 Hz, 2 H) 8.33 (d, J=8.20 Hz, 2 H) 12.32 (br. s., 1 H). LC-MS calcd. for Ci₆Hi₅F₃N₃0 [(M+H)⁺] 322, obsd. 322.0. Example 52

7-Allyl-2-(4^rifluoromethyl^henyl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-

From 7-allyl-2-chloro-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (Intermediate E) and 4- (trifluoromethyl)phenylboronic acid: 7-allyl-2-(4-trifluoromethyl-phenyl)-3,7-dihydro- pyrrolo[2,3-d]pyrimidin-4-one was obtained a light yellow solid (82.2 mg, 60.3%). ^!H NMR (400 MHz, DMSO- e) δ ppm 4.85 (d, J=5.47 Hz, 2 H) 5.05 (dd, J=16.80, 1.56 Hz, 1 H) 5.19 (dd, J=10.35, 1.37 Hz, 1 H) 5.95 - 6.20 (m, 1 H) 6.57 (d, J=3.52 Hz, 1 H) 7.19 (d, J=3.13 Hz, 1 H) 7.90 (d, J=8.59 Hz, 2 H) 8.34 (d, J=8.20 Hz, 2 H) 12.37 (br. s., 1 H). LC-MS calcd. for C16H13F3N3O [(M+H)⁺] 320, obsd. 320.0.

Example 53

7-(3,4-Dihydroxy-butyl)-2-(4-trifluoromethyl-phenyl)-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4-one

A solution of 7-but-3-enyl-2-(4-trifluoromethyl-phenyl)-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4-one (50.3 mg, 151 μηιοΐ) in acetone (1.2 mL) and water (0.4 mL) was treated with potassium permanganate (46.1 mg, 292 μηιοΐ). The reaction stirred at room temperature overnight. The reaction was filtered through a coarse sintered glass frit, rinsing with ethyl acetate. The filtrate was concentrated in vacuo and then partitioned between water (25 mL) and ethyl acetate (25 mL). The aqueous layer was back extracted with ethyl acetate (25 mL), and the combined organics were washed with a saturated aqueous sodium chloride solution (25 mL), dried over magnesium sulfate, filtered and rinsed with ethyl acetate, and concentrated in vacuo. Flash chromatography (24 g silica gel column, 1-10% methanol/methylene chloride) afforded 7- (3 ,4-dihydroxy-butyl)-2 -(4 ^ri fluoromem^

as a white solid (6.9 mg, 12.4%). 1H NMR (300 MHz, DMSO-d₆) δ ppm 1.72 (s, 1 H) 1.85 - 2.15 (m, 1 H) 3.10 - 3.53 (m, 3 H) 4.09 - 4.45 (m, 2 H) 4.48 - 4.62 (m, 1 H) 4.72 (d, J=5.09 Hz, 1 H) 6.53 (d, J=3.20 Hz, 1 H) 7.12 - 7.34 (m, 1 H) 7.90 (d, J=8.29 Hz, 2 H) 8.34 (d, J=8.48 Hz, 2 H) 12.31 (s, 1 H). LC-MS calcd. for Ci₇Hi₇F₃N₃0₃ [(M+H)⁺] 368, obsd. 368.0.

In an analogous manner the following compound was synthesized following the above procedure:

Example 54

7-(2,3-Dihydroxy-propyl)-2-(4-trifiuoromethyl-phenyl)-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4-one

From 7-allyl-2-(4-trifluoromethyl-phenyl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one , 7-(2 ,3 -dihydroxy-propyl)-2-(4-trifluoromethyl-phenyl)-3 ,7-dihydro-pyrrolo [2 ,3 -d]pyrimidin-4- one was obtained as a light yellow solid (2.6 mg, 8.39%). ^!H NMR (400 MHz, DMSO-d₆) δ ppm 3.87 (br. s., 1 H) 4.08 (dd, J=13.87, 7.62 Hz, 1 H) 4.35 (dd, J=13.87, 4.10 Hz, 1 H) 4.75 (t, J=5.66 Hz, 1 H) 5.01 (d, J=5.47 Hz, 1 H) 6.51 (d, J=3.13 Hz, 1 H) 7.21 (d, J=3.52 Hz, 1 H) 7.90 (d, J=8.59 Hz, 2 H) 8.33 (d, J=8.20 Hz, 2 H) 12.31 (br. s., 1 H). LC-MS calcd. for Ci₆Hi₅F₃N303 [(M+H)⁺] 354, obsd. 354.0.

Example 55 N-Ethyl-4-[4-(7-methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)-piperazin- l-yl]-benzamide

Step 1 : A solution of 4-[4-(7-methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2- yl)-piperazin-l-yl]-benzoic acid ethyl ester (163 mg, 427 μηιοΐ) in tetrahydrofuran (1.6 mL) and methanol (0.8 mL) was treated with a IN aqueous sodium hydroxide solution (748 μί, 748 μηιοΐ). The resulting yellow solution was stirred for 3 h at room temperature. At this point, another aliquot of a IN aqueous sodium hydroxide solution (748 μΐ,, 748 μηιοΐ) was added. At this time, the reaction was heated to 75°C where it was stirred for 1.5 h. The reaction was then diluted with water (10 mL) and extracted with ethyl acetate (20 mL). The aqueous layer was acidified to pH 2 with a IN aqueous hydrochloric acid solution and further extracted with ethyl acetate (20 mL). The organic layer was washed with a saturated aqueous sodium chloride solution (10 mL). Since product was not soluble in the organic layer, all of the layers were combined and concentrated in vacuo and dried to afford 4-(4-(7-methyl-4-oxo-4,7-dihydro-3H- pyrrolo[2,3-d]pyrimidin-2-yl)piperazin-l-yl)benzoic acid (193 mg, 128%) as a light grey solid. 1H NMR (300 MHz, DMSO-d₆) δ ppm 3.41 (br. s., 4 H) 3.57 (s, 3 H) 3.71 (br. s., 4 H) 6.25 (d, J=3.39 Hz, 1 H) 6.78 (d, J=3.39 Hz, 1 H) 7.02 (d, J=9.23 Hz, 2 H) 7.79 (d, J=8.85 Hz, 2 H) 10.89 (s, 1 H) 12.29 (s, 1 H). LC-MS calcd. for Ci₈H₂oN₅0₃ [(M+H)⁺] 354, obsd. 354.1.

Step 2: A solution of 4-(4-(7-methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2- yl)piperazin-l-yl)benzoic acid (50.4 mg, 143 μηιοΐ) in methylene chloride (1.22 mL) was treated with N,N-diisopropylethylamine (74.1 mg, 100 μί, 570 μηιοΐ), a 2M solution of ethylamine in tetrahydrofuran (86 μΐ,, 172 μηιοΐ), l-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (49.8 mg, 260 μηιοΐ) and 1-hydroxybenzotriazole (28.9 mg, 214 μηιοΐ). The resulting white suspension was stirred at room temperature overnight. At this time, the reaction was diluted with methylene chloride (25 mL) and methanol (5 mL), and was washed with a IN aqueous hydrochloric acid solution (25 mL), a saturated aqueous sodium bicarbonate solution (25 mL), water (25 mL), and a saturated aqueous sodium chloride solution (25 mL). The organic layer was dried over magnesium sulfate and concentrated in vacuo onto Celite®. The product remained in the aqueous layer, so it was extracted with a solution of 10% methanol/methylene chloride (6 x 25 mL). The combined organics were concentrated in vacuo onto Celite®. Flash chromatography (10 g silica gel column, 1-10% methanol/methylene chloride) afforded N-ethyl- 4-[4-(7-methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)-piperazin-l-yl]-benzamide (5.1 mg, 9.4%) as a white solid. 1H NMR (300 MHz, DMSO-d₆) δ ppm 1.10 (t, J=7.35 Hz, 3 H) 3.32 (s, 4 H) 3.57 (s, 3 H) 3.70 (br. s., 4 H) 6.25 (d, J=3.20 Hz, 1 H) 6.78 (d, J=3.39 Hz, 1 H) 7.00 (d, J=8.67 Hz, 2 H) 7.74 (d, J=9.23 Hz, 2 H) 8.19 (s, 1 H) 10.88 (s, 1 H). LC-MS calcd. for C₂oH2₅N₆02 [(M+H)⁺] 381 , obsd. 381.1

Example 56 7-Methyl-2-pyrazol- 1 -yl-3 ,7-dihydro-pyrrolo[2 ,3 -d]pyrimidin-4-one

A high pressure microwave reaction vial was charged with 2-chloro-7-methyl-3,7- dihydro-pyrrolo[2,3-d]pyrimidin-4-one (Intermediate A) (32.7 mg, 178 μηιοΐ) and anhydrous tetrahydrofaran (0.5 mL). The reaction was then treated with lH-pyrazole (22.3 mg, 328 μηιοΐ). The vial was tightly sealed and affixed behind a blast shield. The reaction was warmed to 100°C where it stirred overnight. At this time, the reaction was heated at 100°C for 30 min in a microwave. The reaction was concentrated in vacuo onto silica gel. Flash chromatography (12 g silica gel column, 1-10% methanol/methylene chloride) afforded 7-methyl-2-pyrazol-l-yl-3,7- dihydro-pyrrolo[2,3-d]pyrimidin-4-one as a white solid (9.6 mg, 25%). ^!H NMR (300 MHz, DMSO- e) δ ppm 3.74 (s, 3 H) 6.50 (d, J=3.39 Hz, 1 H) 6.67 (dd, J=2.54, 1.79 Hz, 1 H) 7.10 (d, J=3.20 Hz, 1 H) 7.91 (d, J=1.13 Hz, 1 H) 8.61 (d, J=2.45 Hz, 1 H) 11.82 (br. s., 1 H). LC-MS calcd. for Ci₀Hi₀N₅O [(M+H)⁺] 216, obsd. 215.9.

Example 57 7-Hydroxymethyl-2-(4-trifluoromethyl-phenyl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4- one

Step 1 : A solution of 2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine (0.30 g, 1.6 mmol) in anhydrous N,N-dimethylformamide (5.5 mL) cooled to 0°C was treated with a 60% dispersion of sodium hydride in mineral oil (82.5 mg, 2.06 mmol) under nitrogen. The reaction was stirred at 0°C for 20-25 min. At this time, the reaction was treated with (2- (chloromethoxy)ethyl)trimethylsilane (340 μί, 1.92 mmol) and was purged with nitrogen. The ice/water bath was removed, and the reaction was stirred at room temperature over 3 nights. At this time, the reaction was diluted with water (50 mL) and was extracted with ethyl acetate (2 x 50 mL). The combined organics were washed with water (50 mL) and a saturated aqueous sodium chloride solution (50 mL), dried over magnesium sulfate, filtered and rinsed with ethyl acetate, and concentrated in vacuo onto Celite®. Flash chromatography (12 g silica gel column, 1-30% ethyl acetate/hexanes) afforded 2,4-dichloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H- pyrrolo[2,3-d]pyrimidine as a viscous yellow oil (336.5 mg, 66.3%). 1H NMR (300 MHz, DMSO- e) δ ppm -0.18 - -0.01 (m, 9 H) 0.74 - 0.94 (m, 2 H) 3.43 - 3.62 (m, 2 H) 5.60 (s, 2 H) 6.78 (d, J=3.77 Hz, 1 H) 7.90 (d, J=3.77 Hz, 1 H). LC-MS calcd. for Ci₂Hi₈Cl₂N₃OSi [(M+H)⁺] 318, obsd. 317.9.

Step 2: A solution of 2,4-dichloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3- d]pyrimidine (336.5 mg, 1.06 mmol) in tetrahydrofuran (6 mL) was treated with a 2N aqueous potassium hydroxide solution (6 mL) and was warmed to 80°C, where it stirred overnight. At this time, the reaction was concentrated in vacuo and was then carefully brought to pH ~7 with a 2N aqueous hydrochloric acid solution. The material was then diluted with water (25 mL) and extracted with a 10% methanol/methylene chloride solution (2 x 25 mL). The combined organics were dried over magnesium sulfate, filtered and rinsed with methylene chloride, and concentrated in vacuo onto Celite®. Flash chromatography (40 g silica gel column, 1-50% ethyl acetate/hexanes) afforded 2-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-3H-pyrrolo[2,3- d]pyrimidin-4(7H)-one as an off-white solid (53.7 mg, 16.9%). 1H NMR (300 MHz, DMSO-d₆) δ ppm -0.08 (s, 9 H) 0.82 (t, J=8.10 Hz, 2 H) 3.50 (t, J=8.10 Hz, 2 H) 5.42 (s, 2 H) 6.53 (d, J=3.20 Hz, 1 H) 7.26 (br. s., 1 H) 12.98 (br. s., 1 H). LC-MS calcd. for Ci₂Hi₉ClN₃0₂Si [(M+H)⁺] 300, obsd. 300.0.

Step 3: A microwave reaction vial was charged with 2-chloro-7-((2- (trimethylsilyl)ethoxy)methyl)-3H-pyrrolo[2,3-d]pyrimidin-4(7H)-one (53.7 mg, 179 μηιοΐ) and ethanol (850 μί) (650 \L + 200 rinse). The resulting mixture was treated with a 2M aqueous sodium carbonate solution (270 μΐ,, 540 μηιοΐ), 4-(trifluoromethyl)phenylboronic acid (42.1 mg, 222 μηιοΐ), and tetrakis(triphenylphosphine)palladium(0) (13.2 mg, 11.4 μηιοΐ). The vial was tightly sealed and heated in a microwave at 150°C for 8 min. At this time, the reaction was filtered through a pad of Celite^®, rinsing copiously with methanol, and the filtrate was concentrated in vacuo onto Celite^®. Flash chromatography (12 g silica gel column, 10-40% ethyl acetate/hexanes) afforded 2-(4-(trifluoromethyl)phenyl)-7-((2-(trimethylsilyl)ethoxy)methyl)- 3H-pyrrolo[2,3-d]pyrimidin-4(7H)-one as a light yellow solid (47.7 mg, 65.0%). ^!H NMR (300 MHz, DMSO-de) δ ppm -0.13 (s, 9 H) 0.85 (t, J=8.10 Hz, 2 H) 3.56 (t, J=8.10 Hz, 2 H) 5.58 (s, 2 H) 6.59 (d, J=3.39 Hz, 1 H) 7.34 (d, J=3.39 Hz, 1 H) 7.90 (d, J=7.91 Hz, 2 H) 8.36 (d, J=8.29 Hz, 2 H) 12.45 (s, 1 H). LC-MS calcd. for Ci₉H₂₃F₃N₃0₂Si [(M+H)⁺] 410, obsd. 410.1. Step 4: A solution of 2-(4-(trifluoromethyl)phenyl)-7-((2-(trimethylsilyl)ethoxy)methyl)- 3H-pyrrolo[2,3-d]pyrimidin-4(7H)-one (47.7 mg, 116 μηιοΐ) in anhydrous methylene chloride (6.0 mL) was cooled, under nitrogen, to 0°C. The solution was then treated portion-wise with trifiuoro acetic acid (1.5 mL). The reaction was stirred under nitrogen at 0°C for 30 min. At this time, the reaction was warmed to room temperature where it continued to stir for an additional 3 h. At this time, the reaction was diluted with methylene chloride and was concentrated in vacuo onto Celite^® while maintaining a water bath temperature less than or equal to 30°C. Flash chromatography (12 g silica gel column, 40-70% ethyl acetate/hexanes) afforded 7- hydroxymethyl-2-(4-trifiuoromethyl-phenyl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one as an off-white solid (20.9 mg, 58.0%). 1H NMR (300 MHz, DMSO-d₆) δ ppm 5.55 (d, J=7.91 Hz, 2 H) 6.56 (d, J=3.39 Hz, 1 H) 6.63 (t, J=7.35 Hz, 1 H) 7.27 (d, J=3.39 Hz, 1 H) 7.91 (d, J=8.48 Hz, 2 H) 8.37 (d, J=8.10 Hz, 2 H) 12.38 (s, 1 H). LC-MS calcd. for C14H11F3N3O2 [(M+H)⁺] 310, obsd. 310.0.

Example 58 7-Methyl-2-(3-methyl-3-phenyl-azetidin-l-yl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4- one

A mixture of 2-(3-(4-bromophenyl)-3-methylazetidin-l-yl)-7-methyl-3H-pyrrolo[2,3- d]pyrimidin-4(7H)-one (100.3 mg, 269 μηιοΐ) in ethyl acetate (2.7 mL) and methanol (2.8 mL) was treated with 10% palladium on carbon (9.2 mg, -10% weight of starting material used). The flask was capped with a rubber septum and a hydrogen balloon was attached. The reaction was stirred at room temperature overnight. At this time, the reaction was concentrated in vacuo onto Celite®. Flash chromatography (24 g silica gel column, 20-100% ethyl acetate/hexanes) afforded 7-methyl-2-(3-methyl-3-phenyl-azetidin-l-yl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one as an off-white solid (43.2 mg, 54.6%). ^!H NMR (300 MHz, DMSO-d₆) δ ppm 1.61 (s, 3 H) 3.53 (s, 3 H) 4.10 (d, J=8.67 Hz, 2 H) 4.24 (d, J=8.29 Hz, 2 H) 6.23 (d, J=3.01 Hz, 1 H) 6.73 (d, J=3.20 Hz, 1 H) 7.13 - 7.50 (m, 5 H) 10.90 (s, 1 H). LC-MS calcd. for C17H19N4O [(M+H)⁺] 295, obsd. 295.1.

Example 59 7-Cyclopropyl-2-(4^rifluoromethyl-phenyl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-

Step 1 : A mixture of 2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine (210 mg, 1.12 mmol) in methylene chloride (4.86 mL) was treated with triethylamine (314 μΐ,, 2.26 mmol), copper(II) acetate monohydrate (232 mg, 1.16 mmol) and cyclopropylboronic acid (95.9 mg, 1.12 mmol). The reaction was stirred at room temperature overnight. At this time, the reaction was warmed to 70°C for 3 h. At this time, the reaction was treated with additional triethylamine (314 μΐ,, 2.26 mmol), copper(II) acetate monohydrate (232 mg, 1.16 mmol) and cyclopropylboronic acid (95.9 mg, 1.12 mmol). The reaction was allowed to stir overnight at room temperature. At this time, the reaction was filtered through a plug of Celite®, washing with a 10% methanol/methylene chloride solution. The filtrate was concentrated in vacuo onto silica gel. Flash chromatography (24 g silica gel column, 2-20% ethyl acetate/hexanes) afforded 2,4-dichloro-7-cyclopropyl-7H- pyrrolo[2,3-d]pyrimidine as an off-white solid (70 mg, 27.5%). 1H NMR (300 MHz, DMSO-d₆) δ ppm 0.82 - 1.28 (m, 4 H) 3.62 (s, 1 H) 6.66 (d, J=3.58 Hz, 1 H) 7.73 (d, J=3.39 Hz, 1 H). LC- MS calcd. for C₉H₈C1₂N3 [(M+H)⁺] 228, obsd. 227.9.

Step 2: A mixture of 2,4-dichloro-7-cyclopropyl-7H-pyrrolo[2,3-d]pyrimidine (68 mg, 298 μηιοΐ) in a 2N aqueous potassium hydroxide solution (1.67 ml, 3.34 mmol) was heated to 100°C overnight. At this time, the reaction was cooled to room temperature. The reaction was diluted with water (~50 mL) and then neutralized by the addition of a 2N aqueous hydrochloric acid solution. The product was extracted into a 10% methanol/methylene chloride solution (3 x 25 mL), dried over sodium sulfate, filtered and concentrated in vacuo to afford 2-chloro-7- cyclopropyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one as a light yellow solid (59.9 mg, 95.8%). ^!H NMR (300 MHz, DMSO-d₆) δ ppm 0.78 - 1.17 (m, 4 H) 3.50 (s, 1 H) 6.42 (d, J=3.39 Hz, 1 H) 7.07 (br. s., 1 H) 12.87 (br. s., 1 H). LC-MS calcd. for C9H9CIN3O [(M+H)⁺] 210, obsd. 209.9.

Step 3: A microwave reaction vial was charged with 2-chloro-7-cyclopropyl-3,7-dihydro- pyrrolo[2,3-d]pyrimidin-4-one (57 mg, 272 μηιοΐ), 4-(trifluoromethyl)phenylboronic acid (62.0 mg, 326 μηιοΐ), a 2M aqueous sodium carbonate solution (408 μΐ,, 816 μηιοΐ), and tetrakis(triphenylphosphine)palladium(0) (15.7 mg, 13.6 μηιοΐ) in ethanol (1.09 mL). The reaction mixture was heated in a microwave at 150°C for 8 min. At this time, the reaction was diluted with methylene chloride and was filtered through a pad of Celite®, washing with a 10% methanol/methylene chloride solution. The filtrate was dried over sodium sulfate, filtered, and concentrated in vacuo onto Celite®. Flash chromatography (12 g silica gel column, 25-50% ethyl acetate/hexanes) afforded 7-cyclopropyl-2-(4-trifluoromethyl-phenyl)-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4-one as a white solid (48.5 mg, 55.9%). ^!H NMR (300 MHz, DMSO-d₆) δ ppm 0.71 - 1.29 (m, 4 H) 3.65 (d, J=4.90 Hz, 1 H) 6.49 (d, J=3.58 Hz, 1 H) 7.15 (d, J=3.39 Hz, 1 H) 7.91 (d, J=8.67 Hz, 2 H) 8.35 (d, J=7.91 Hz, 2 H) 12.35 (br. s., 1 H). LC-MS calcd. for C16H13F3N3O [(M+H)⁺] 320, obsd. 320.0. Example 60

2-[4-(2-Fluoro-phenyl)-piperazin-l-yl]-7-hydroxymethyl-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4-one

Step 1 : A solution of 2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine (0.30 g, 1.6 mmol) in anhydrous N,N-dimethylformamide (5.5 mL) cooled to 0°C was treated with a 60% dispersion of sodium hydride in mineral oil (82.5 mg, 2.06 mmol) under nitrogen. The reaction was stirred at 0°C for 20-25 min. At this time, the reaction was then treated with (2- (chloromethoxy)ethyl)trimethylsilane (340 μί, 1.92 mmol) and was purged with nitrogen. The ice/water bath was removed, and the reaction was allowed to warm to room temperature where it stirred over 3 nights. At this time, the reaction was diluted with water (50 mL) and was extracted with ethyl acetate (2 x 50 mL). The combined organics were washed with water (50 mL) and a saturated aqueous sodium chloride solution (50 mL), dried over magnesium sulfate, filtered and rinsed with ethyl acetate, and concentrated in vacuo onto Celite®. Flash chromatography (12 g silica gel column, 1-30% ethyl acetate/hexanes) afforded 2,4-dichloro-7-((2-

(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine as a viscous yellow oil (336.5 mg, 66.3 %). 1H NMR (300 MHz, DMSO-d₆) δ ppm -0.26 - 0.05 (m, 9 H) 0.74 - 0.98 (m, 2 H) 3.44 - 3.65 (m, 2 H) 5.60 (s, 2 H) 6.78 (d, J=3.77 Hz, 1 H) 7.90 (d, J=3.77 Hz, 1 H). LC-MS calcd. for Ci₂Hi₈Cl₂N₃OSi [(M+H)⁺] 318, obsd. 317.9. Step 2: A solution of 2,4-dichloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3- d]pyrimidine (336.5 mg, 1.06 mmol) in tetrahydrofuran (6 mL) was treated with a 2N aqueous potassium hydroxide solution (6 mL). The reaction was warmed to 80°C where it stirred overnight. At this time, the reaction was concentrated in vacuo. The resulting mixture was then carefully brought to pH ~7 with a 2N aqueous hydrochloric acid solution, diluted with water (25 mL) and extracted with a 10% methanol/methylene chloride solution (2 x 25 mL). The combined organics were dried over magnesium sulfate, filtered and rinsed with methylene chloride and concentrated in vacuo onto Celite®. Flash chromatography (40 g silica gel column, 1-50% ethyl acetate/hexanes) afforded 2-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-3H-pyrrolo[2,3- d]pyrimidin-4(7H)-one as an off-white solid (53.7 mg, 16.9 %). 1H NMR (300 MHz, DMSO-d₆) δ ppm -0.08 (s, 9 H) 0.82 (t, J=8.10 Hz, 2 H) 3.50 (t, J=8.10 Hz, 2 H) 5.42 (s, 2 H) 6.53 (d, J=3.20 Hz, 1 H) 7.26 (br. s., 1 H) 12.98 (br. s., 1 H). LC-MS calcd. for

[(M+H)⁺] 300, obsd. 300.0.

Step 3: A high pressure reaction vial was charged with 2-chloro-7-((2- (trimethylsilyl)ethoxy)methyl)-3H-pyrrolo[2,3-d]pyrimidin-4(7H)-one (50 mg, 175 μηιοΐ) and ethanol (460 μί). The reaction was treated with l-(2-fluorophenyl)piperazine (63.1 mg, 55.3 μί, 350 μηιοΐ) and was sealed. The reaction was then heated to 100°C where it stirred overnight. At this time, the reaction was allowed to cool to room temperature. It was then diluted with methylene chloride and methanol and concentrated in vacuo onto Celite®. Flash chromatography (12 g silica gel column, 1-10% methylene chloride/methanol) afforded 2-(4-(2- fluorophenyl)piperazin- 1 -yl)-7 -((2 -(trimethylsilyl)ethoxy)methyl)-3H-pyrrolo [2 ,3 -d]pyrimidin- 4(7H)-one as a purple oil (31.5 mg, 40.6%). ^!H NMR (400 MHz, DMSO-d₆) δ ppm -0.32 - 0.07 (m, 9 H) 0.84 (t, J=8.01 Hz, 2 H) 3.07 (br. s., 4 H) 3.51 (t, J=8.01 Hz, 2 H) 3.73 (br. s., 4 H) 5.34 (s, 2 H) 6.31 (d, J=3.52 Hz, 1 H) 6.89 (d, J=3.52 Hz, 1 H) 6.95 - 7.25 (m, 4 H) 10.83 - 11.10 (m, 1 H). LC-MS calcd. for C₂₂H3iFN₅0₂Si [(M+H)⁺] 444, obsd. 444.1.

Step 4: A solution of 2-(4-(2-fluorophenyl)piperazin-l-yl)-7-((2- (trimethylsilyl)ethoxy)methyl)-3H-pyrrolo[2,3-d]pyrimidin-4(7H)-one (30 mg, 67.6 μηιοΐ) in methylene chloride (3.38 mL) was treated dropwise with trifluoroacetic acid (1.13 mL). The reaction was stirred at room temperature for 2 h, and was then concentrated in vacuo onto Celite®. Flash chromatography (12 g silica gel column, 40-80% ethyl acetate/hexanes) afforded 2-[4-(2-fluoro-phenyl)-piperazin-l-yl]-7-hydroxymethyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4- one as a light grey solid (11.2 mg, 48.2%). ^!H NMR (400 MHz, DMSO-d₆) δ ppm 2.97 - 3.15 (m, 4 H) 3.71 (d, J=5.08 Hz, 4 H) 5.32 (d, J=7.42 Hz, 2 H) 6.28 (d, J=3.52 Hz, 1 H) 6.31 - 6.39 (m, 1 H) 6.85 (d, J=3.52 Hz, 1 H) 6.93 - 7.21 (m, 4 H) 10.89 (s, 1 H). LC-MS calcd. for Ci₇Hi₉FN₅0₂ [(M+H)⁺] 344, obsd. 344.1.

Example 61

2-(4-(2,6-difiuorophenyl)piperazin-l-yl)-7-(2,3-dihydroxypropyl)-3H-pyrrolo[2,3- d]pyrimidin-4(7H)-one

Step 1 : A mixture of 7-allyl-2-chloro-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (Intermediate E, 40.8 mg, 195 μηιοΐ), 4-methylmorpholine N-oxide (11.4 mg, 97.3 μηιοΐ), and potassium osmate(VI) dihydrate (717 μg, 1.95 μηιοΐ) in teri-butanol (730 μί) and water (243 μί) cooled to 0°C was treated with a 50% aqueous hydrogen peroxide solution (20 μΐ,, 292 μηιοΐ). The reaction was allowed to warm to room temperature, where it stirred overnight. At this time, the reaction was diluted with methanol and absorbed onto Celite®. Flash chromatography (4 g silica gel column, 2-8% methanol/methylene chloride) afforded 2-chloro-7- (2,3-dihydroxy-propyl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one as an off-white solid (16.4 mg, 34.6%). 1H NMR (300 MHz, DMSO-d₆) δ ppm 3.57 (s, 1 H) 3.80 (d, J=9.42 Hz, 1 H) 3.85 - 3.99 (m, 1 H) 4.14 - 4.29 (m, 1 H) 4.75 (t, J=5.75 Hz, 1 H) 4.98 (d, J=5.46 Hz, 1 H) 6.46 (d, J=3.39 Hz, 1 H) 7.12 (d, J=3.20 Hz, 1 H) 12.80 (s, 1 H). LC-MS calcd. for C₉H₁₁CIN₃O₃ [(M+H)⁺] 244, obsd. 243.9.

Step 2: A mixture of 2-chloro-7-(2,3-dihydroxy-propyl)-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4-one (16 mg, 65.7 μηιοΐ) in ethanol (460 μί) was treated with l-(2,6- difluorophenyl)piperazine trifiuoroacetic acid salt (40.9 mg, 131 μηιοΐ) and N,N- diisopropylethylamine (36.6 μΐ,, 210 μηιοΐ). The reaction was heated to 100°C, where it stirred overnight. At this time, the reaction was allowed to cool to room temperature. The reaction was then diluted with methylene chloride and methanol and concentrated in vacuo onto Celite®. Flash chromatography (4 g silica gel column, 1-4% methanol/methylene chloride) afforded 2-[4- (2,6-difluoro-phenyl)-piperazin-l-yl]-7-(2,3-dihydroxy-propyl)-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4-one as a purple solid (15.3 mg, 57.5%). ^!H NMR (400 MHz, DMSO-d₆) δ ppm 3.17 (br. s., 4 H) 3.23 - 3.31 (m, 2 H) 3.54 - 3.70 (m, 4 H) 3.71 - 3.93 (m, 2 H) 4.09 (dd, J=13.68, 4.39 Hz, 1 H) 4.67 (t, J=5.77 Hz, 1 H) 4.94 (d, J=5.27 Hz, 1 H) 6.24 (d, J=3.51 Hz, 1 H) 6.80 (d, J=3.51 Hz, 1 H) 6.95 - 7.24 (m, 3 H) 10.85 (br. s., 1 H). LC-MS calcd. for Ci₉H₂₂F₂N₅0₃ [(M+H)⁺] 406, obsd. 406.0.

Example 62

7-Methyl-2-phenyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one

Step 1 : A solution of 2-phenyl-3,7-dihydro-pyrrolo[2,3,-d]pyrimidin-4-one (100 mg, 0.47 mmol) and triethylamine (144 mg, 1.42 mmol) in tetrahydrofuran (3 mL) was treated with chlorotriethylsilane (71.4 mg, 0.47 mmol) at room temperature. After stirring at room temperature for 4 h, the reaction mixture was filtered through a pad of Celite® and was washed with diethyl ether. The filtrate was concentrated in vacuo. The resulting residue was partitioned between a saturated aqueous sodium bicarbonate solution and ethyl acetate. The aqueous layer was extracted with ethyl acetate. The combined organics were concentrated in vacuo to afford 2- phenyl-4-triethylsilanyloxy-7-H-pyrrolo[2,3,-d]pyrimidine. The material was used without further purification.

Step 2: A solution of 2-phenyl-4-triethylsilanyloxy-7-H-pyrrolo[2,3,-d]pyrimidine (70 mg, 0.22 mmol) in tetrahydrofuran (2 mL) cooled to 0°C was treated with a 60% dispersion of sodium hydride in mineral oil (25.8 mg, 1.08 mmol) and iodomethane (61.1 mg, 0.43 mmol). After stirring for 20 min, the reaction mixture was poured onto a saturated aqueous ammonium chloride solution and was extracted with ethyl acetate. The combined organics were washed with a saturated aqueous sodium chloride solution and were concentrated in vacuo. Flash chromatography (40/1 methylene chloride/methanol) afforded 7-methyl-2-phenyl-3,7-dihydro- pyrrolo[2,3,-d]pyrimidine-4-one (12 mg, 24.8%) as a white solid. 1H NMR (400 MHz, DMSO- d₆) δ ppm 3.78 (s, 3 H) 6.50 (d, J=3.51 Hz, 1 H) 7.15 (d, J=3.26 Hz, 1 H) 7.41 - 7.68 (m, 3 H) 8.09 - 8.25 (m, 2 H) 12.10 (s, 1 H); LC-MS calcd. for C13H12N3O [(M+H)⁺] 226, obsd. 225.9.

Example 63

2-[4-[2 6-difluoro-4-(2-methoxyethoxy)phenyl]piperazin- 1 -yl]-7-(2-hydroxyethyl)-3H- pyrrolo[2 3-d]pyrimidin-4-one

A solution of 2-chloro-7-(2-hydroxyethyl)-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-one (150 mg, 0.70 mmol, 1.00 equiv), l-[2,6-difiuoro-4-(2-methoxyethoxy)phenyl]piperazine (192 mg, 0.71 mmol, 1.00 equiv) and DIEA (182 mg, 1.41 mmol, 2.00 equiv) in ethanol (2 mL) was placed in an 8-mL sealed tube. The reaction mixture was irradiated with microwave radiation for 30 min at 140°C and then cooled back to room temperature. The crude product was collected by filtration then purified by Prep-HPLC with the following conditions (Prep-HPLC-005): Column: XBridge Prep C₁₈ OBD Column, 5 um, 19*150 mm; mobile phase: water with 10 mmol NH₄HCO₃ and MeCN (MeCN 35.0%, MeCN up to 50.0% in 10 min, up to 95.0% in 1 min, hold 95.0% in 1 min, down to 35.0% in 2 min); Detector, UV 254/220 nm to yield 98.3 mg (31%) of 2-[4-[2,6-difiuoro-4-(2-methoxyethoxy)phenyl]piperazin-l-yl]-7-(2-hydroxyethyl)-3H,4H,7H- pyrrolo [2,3-d]pyrimidin-4-one as a white solid. ^!HNMR (400MHz, DMSO-i ) 5 ppm 3.09-3.06 (m, 4H), 3.28 (s, 3H), 3.69-3.61 (m, 8H), 4.02-3.99 (m, 2H), 4.08-4.06 (m, 2H), 4.85 (t, J = 5.6 Hz, 1H), 6.23 (d, J = 3.2 Hz, 1H), 6.72 (d, J = 11.2 Hz, 2H), 6.81 (d, J = 3.2Hz, 1H), 10.81 (s, 1H). LC-MS calcd. for C₂iH26F₂N₅0₄ [(M+H)⁺] 450, obsd. 450.3.

Example 64 μΗΤ8-ΤΝΚ8-Γ>νΤ2 TR-FRET Binding Assay

(10 μΕ/well in BD1536-well plate, a single point)

Reagents and Stock Solutions Tankyrase 1 (TNKS1): 184.3 μΜ= 5.2 mg/mL His6-TNKS1, MW=28.2 KDa (construct:

1088-1327, 1266M ) in 20 mM Tris pH 8, 150 mM NaCl, 10 % glycerol, and 0.5 mM TCEP

Alternatively, in place of His6-TNKS1 can use either His6-tankyrase 2 (construct: 934 - 1166) (His6-TNKS2) or His6-PARP1 (full length).

Biotin-IWR2: 10 mM Biotin-IWR2 stock in DMSO, stored at -20 °C. Positive control: 10 mM XAV 939 in DMSO, stored at -20 °C Eu-Streptavidin: 38.1 μΜ (2.1 mg/niL) Eu-SA (Bio# Eu-2212, Lot# N 18001-BDHO2)

APC-anti-His Ab: 8.50 μΜ SL-APC, 8.26 μΜ anti-6His antibody-SureLight APC (Columia Bioscience, Cat# D3-1711 , Lot# N01010-AAH04)

Assay plate: BD 1536-well, clear/black plate (Cat# 353255) NP-40: 10% NP-40 solution (PIERCE, Cat# 28324, Lot # 97101671)

Assay Buffer Preparation

Assay buffer la (ABla) for TNKS dilution: 50 mM Tris, pH 7.4, 100 mM sodium chloride solution, ImM magnesium chloride solution, 1 mM DL-dithiothreitol solution, 0.2 mg/niL bovine serum albumin solution, 0.025% NP-40. Assay buffer lb (ABlb) for Biotin-IWR2 dilution: 50 mM Tris, pH 7.4, 100 mM sodium chloride solution, ImM magnesium chloride solution, 1 mM DL-dithiothreitol solution, 0.2 mg/niL bovine serum albumin solution, 0.05% NP-40

Assay buffer lc (AB lc) for compound dilution: 50 mM Tris, pH 7.4, 100 mM sodium chloride solution, ImM magnesium chloride solution, 1 mM DL-dithiothreitol solution, 0.2 mg/niL bovine serum albumin solution

Assay buffer 2 (AB2) for Eu/APC: 50 mM Tris, pH 7.4, 100 mM sodium chloride solution, ImM magnesium chloride solution, 0.2 mg/niL bovine serum albumin solution

Reagent Stock Solution Preparation

Prepare Biotinylated IWR2 stock solution (3.33x stock) for TOTL and cpd wells : 200 nM Biotin-IWR2 in 5% DMSO/AB lb buffer

Prepare BLANK well stock solution: 5% DMSO/AB lb buffer

Prepare POSITIVE CONTROL well stock solution (3.33x stock): 200 nM XAV939 in 200 nM Biotin-IWR2/5% DMSO/AB lb buffer

Prepare TNKS1 stock solution (5x stock): 300 nM TNKS in ABla buffer

(Alternatively, use TNKS2 or PARP1 stock solutions.) Prepare Eu/APC stock solution (5x stock): 3.5 nM Eu-SA/50 nM APC-His6Ab in AB2 buffer

ASSAY PROCEDURE Compound preparations:

Add 25 μΕΛνεΙΙ 1.5% DMSO /AB lc buffer in each compound well to the compound concentration at 74 μΜ in 8.8 % DMSO /ABlc buffer or in the 2 DMSO CONTROL wells (BLANK, TOTAL and POSITIVE wells) in the compound plate.

Transfer 3 μΕΛνεΙΙ above solution (solution 1,2,3) to an empty assay plate (BD1536-well plate) as follows:

TOTL and cpd wells: Solution 1 (Biotin-IWR2):

BLNK wells: Solution 2 (No Biotin-IWR2):

POSITIVE CONTROL wells: Solution 3 (Biotin-IWR2 + XAV939)

Transfer 3 μΕ/well of the above diluted compound solutions or compound dilution buffer to the above assay plate.

Add 2 μΐ, /well of 300 nM TNKS stock solution (4) to every well in the above assay plate.

Centrifuge the assay plate at 2100 rpm for 2 minutes. Incubate the assay plate at 26 °C for 30 minutes. Centrifuge the assay plate at 2100 rpm for 2 minutes. Incubate the assay plate at 26 °C for 60 minutes.

Read the assay plate immediately at excitation wavelength of 330 nM and emission wavelength of 615 and 665 nM in time resolved fluorescence mode.

Final Assay Conditions

Biotin-IWR2: 60 nM TNKS: 60 nM

Eu-SA: 0.7 nM

APC-His Ab: ΙΟ ηΜ

XAV939 (+ve control): 60 nM at -70 % Inhibition General Library compounds: 22.23 μΜ in 4% DMSO Example 65 TNKS1 NAM Assay

NADase activity of Tankyrase 1 was measured by quantifying released nicotinamide using liquid chromatography mass spectrometry. Varying concentrations of experimental compounds were incubated in 10 reactions containing 25 nM recombinant Tankyrase 1, 1 mM NAD+, 5μΜ d4-nicotinamide internal standard, 2% DMSO, 50 mM Tris pH 7.5, 5 mM CaCl₂, and 0.01% Triton X-100 for 1 h at RT. Reactions were quenched by mixing 2 μΐ_^ of the reaction mixture with 98 μί of 0.05% formic acid. 1 μί of quenched reaction was loaded onto a reverse phase BEH-Phenyl column (Waters) pre-equilibrated with 1 mM ammonium formate and eluted with a linear gradient to 80%> acetonitrile. Compound IC₅oS were determined by four- parameter curve fitting.

Representative compound data for assays are listed below in Table I. Values are in μΜ.

3 0.042 0.051 1.062

4 0.134 0.118 0.437

5 0.030 0.035 1.182

6 0.034 0.036 2.212

7 0.494 0.405 >50

8 0.190 0.143 0.339

9 0.070 0.063 0.618

10 0.111 0.121 0.603

11 0.358 0.285 0.471

12 1.913 1.835 1.722

13 0.112 0.126 0.604

14 0.466 0.427 0.229

15 0.348 0.192 3.457

16 0.915 1.067 1.258

17 0.027 0.032 1.083 18 0.059 0.059 0.758

19 0.043 0.034 1.052

20 0.031 0.036 1.217

21 0.081 0.090 0.612

22 0.097 0.074 0.453

23 0.028 0.031 42.13

24 0.035 0.047 1.283

25 0.292 0.200 0.557

26 0.204 0.153 1.254

27 5.667 6.786 >50

28 0.040 0.080 3.283

29 0.043 0.045 0.732

30 0.031 0.033 1.401

31 0.155 0.133 0.318

32 0.129 0.090 0.229 33 6.177 6.084 1.119

34 0.025 0.024 1.366

35 0.051 0.059 1.629

36 0.273 0.251 21.05

37 0.110 0.217 1.127

38 0.038 0.045 0.785

39 0.054 0.058 0.854

40 0.117 0.109 0.289

41 0.764 0.568 0.307

42 0.228 0.235 0.166

43 0.110 0.143 1.184

44 0.088 0.084 0.0933

45 0.040 0.039 0.842

46 0.123 0.132 >50

47 0.164 0.135 0.292 48 0.043 0.043 4.7

49 1.283 1.361 >50

50 0.176 0.163 >50

51 0.535 0.640. >50

52 0.750 0.730 >50

53 0.240 0.168 2.383

54 0.425 0.237 13.46

55 0.037 0.040 0.449

56 7.803 9.158 >50

57 0.048 0.065 1.877

58 0.108 0.100 1.313

59 0.545 0.619 >50

60 0.033 0.055 10.61

61 0.034 0.028 14.79

62 0.117 0.154 3.915 63 0.00967²

The features disclosed in the foregoing description, or the following claims, expressed in their specific forms or in terms of a means for performing the disclosed function, or a method or process for attaining the disclosed result, as appropriate, may, separately, or in any combination of such features, be utilized for realizing the invention in diverse forms thereof.

The foregoing invention has been described in some detail by way of illustration and example, for purposes of clarity and understanding. It will be obvious to one of skill in the art that changes and modifications may be practiced within the scope of the appended claims. Therefore, it is to be understood that the above description is intended to be illustrative and not restrictive. The scope of the invention should, therefore, be determined not with reference to the above description, but should instead be determined with reference to the following appended claims, along with the full scope of equivalents to which such claims are entitled.

The patents, published applications, and scientific literature referred to herein establish the knowledge of those skilled in the art and are hereby incorporated by reference in their entirety to the same extent as if each was specifically and individually indicated to be incorporated by reference. Any conflict between any reference cited herein and the specific teachings of this specifications shall be resolved in favor of the latter. Likewise, any conflict between an art-understood definition of a word or phrase and a definition of the word or phrase as specifically taught in this specification shall be resolved in favor of the latter.

Claims

1. A compound of the formula (I)

wherein

Q and X are independently in each occurrence N or CH;

R is selected from the group consisting of hydrogen, Ci_6 alkyl, Ci_6 alkenyl, Ci_6 hydroxyalkyl, Ci-6-dihydroxyalkyl, C3-7 cycloalkyl;

diazabicyclo [2.2.1 Jheptanyl;

Rt is Ci-6 alkyl, Ci_6 alkylsulfonyl, Ci_6 acyl, phenyl or heteroaryl said heteroaryl selected from pyridinyl, pyrazinyl or pyrimidinyl and said phenyl and said heteroaryl optionally substituted by one to three substituents independently selected from the group consisting of halogen, CN, Ci_6 alkylsulfonyl, Ci_6 haloalkyl, Ci_6 hydroxyalkyl, C1-3 alkoxy- C1-3 alkyl, Ci_6 alkoxycarbonyl, carboxy, CONRtbR_4C wherein R_4b and Rt_c are independently in each occurrence hydrogen or C1-3 alkyl and ORt_a wherein Rt_a is selected from the group consisting of (i) hydrogen, (ii) Ci_6 alkyl, (iii) C1-3 alkoxy, (iv) C1-3 alkoxy-Ci-3 alkyl, (v) Ci_6 hydroxyalkyl and (vi) Ci-6 dihydroxyalkyl;

R₃ is selected from the group consisting of hydrogen, Ci_6 alkyl, Ci_6 alkoxy, substituted alkyl, Ci_6 haloalkyl, Ci_6 hydroxyalkyl, Ci_6 dihydroxyalky 1, C1-3 alkoxy-Ci-3 alkyl, halogen, CN, trifluoromethyl, Ci_6 alkoxycarbonyl, Ci_6 alkylsulfonyl, CONR_4bR_4c wherein Rt_b and Rt_c are independently in each occurrence hydrogen or C1-3 alkyl, and OR_3a wherein R_3a is selected from the group consisting of (i) hydrogen, (ii) Ci_6 alkyl, (iii) C1-3 alkoxy-Ci-3 alkyl, (iv) Ci_6 hydroxyalkyl and (v) Ci_6 dihydroxyalkyl; or, a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 of formula (I)

Q and X are independently in each occurrence N or CH; R¹ is selected from the group consisting of hydrogen, Ci_6 alkyl, Ci_6 alkenyl, Ci_6 hydroxyalkyl, Ci-6-dihydroxyalkyl, C3-7 cycloalkyl;

Y is selected from the group consisting of CR⁴R⁵, NR⁴ or -O- wherein R⁵ is hydrogen, Ci-6 alkyl; R₄ is Ci-6 alkyl, Ci_6 alkylsulfonyl, Ci_6 acyl, phenyl or heteroaryl said heteroaryl selected from, pyridinyl, pyrazinyl or pyrimidinyl and said phenyl and said heteroaryl optionally substituted by one to three substituents independently selected from the group consisting of halogen, CN, Ci_6 alkylsulfonyl, Ci_6 haloalkyl, Ci_6 hydroxyalkyl, C₁-3 alkoxy- C₁-3 alkyl, Ci_6 alkoxycarbonyl, carboxy, CONRt_bR_4C wherein R_4b and Rt_c are independently in each occurrence hydrogen or C₁-3 alkyl and ORt_a wherein Rt_a is selected from the group consisting of (i) hydrogen, (ii) Ci_6 alkyl, (iii) C₁-3 alkoxy-Ci-3 alkyl, (iv) Ci_6 hydroxyalkyl and (v) Ci_6 dihydroxyalkyl;

R₆ is halogen or hydrogen;

R3 is selected from the group consisting of hydrogen, Ci-₆ alkyl, substituted alkyl, Ci-₆ haloalkyl, Ci-₆ hydroxyalkyl, Ci-₆ dihydroxyalky 1, C1-3 alkoxy-Ci-3 alkyl, halogen, CN, trifiuoromethyl, Ci-₆ alkoxycarbonyl, Ci-₆ alkylsulfonyl, CONRtbRtc wherein Rt_b and Rt_c are independently in each occurrence hydrogen or C₁-3 alkyl, and OR_3a wherein R_3a is selected from the group consisting of (i) hydrogen, (ii) Ci-₆ alkyl, (iii) C1-3 alkoxy-Ci-3 alkyl, (iv) Ci-₆ hydroxyalkyl and (v) Ci-₆ dihydroxyalkyl; or, a pharmaceutically acceptable salt thereof.

3. The compound of any one of claims 1 -2 wherein: Q and X are independently in each occurrence N or CH;

R¹ is selected from the group consisting of hydrogen, Ci_6 alkyl, Ci_6 alkenyl, Ci_6 hydroxyalkyl, Ci-6-dihydroxyalkyl, C3-7 cycloalkyl;

diazabicyclo [2.2.1 ]heptanyl;

Rt is Ci-6 alkyl, Ci-₆ alkylsulfonyl, Ci-₆ acyl, phenyl or heteroaryl said heteroaryl selected from pyridinyl, pyrazinyl or pyrimidinyl and said phenyl and said heteroaryl optionally substituted by one to three substituents independently selected from the group consisting of halogen, CN, Ci-₆ alkylsulfonyl, Ci-₆ haloalkyl, Ci-₆ alkoxycarbonyl, carboxy, CONRtbR4c wherein Rtb and Rt_c are independently in each occurrence hydrogen or C_1-3 alkyl and ORt_a wherein Rt_a is C_1-3 alkoxy; R₃ is selected from the group consisting of hydrogen, Ci_6 alkyl, Ci_6 alkoxy, Ci_6 haloalkyl, and CN; or, a pharmaceutically acceptable salt thereof.

4. The compound of any one of claims 1 -3 wherein:

Ri is selected from hydrogen or alkyl,

Rt is phenyl or heteroaryl said heteroaryl selected from pyridinyl, pyrazinyl or pyrimidinyl and said phenyl and said heteroaryl optionally substituted by one to three substituents independently selected from the group consisting of halogen, CN, Ci_6 alkylsulfonyl, Ci-6 haloalkyl, Ci_6 hydroxyalkyl, C_1-3 alkoxy- C_1-3 alkyl, Ci_6 alkoxycarbonyl, carboxy, CONRt_bR_4c wherein Rt_b and Rt_c are independently in each occurrence hydrogen or C_1-3 alkyl and ORt_a wherein Rt_a is selected from the group consisting of (i) Ci_6 alkyl, (ii) C_1-3 alkoxy-Ci_₃ alkyl, (iii) Ci_6 hydroxyalkyl and (iv) Ci_₆ dihydroxyalkyl.

5. The compound according to any one of claims 1-4, wherein Q is N.

6. The compound according to any one of claims 1-5, wherein Ri is Ci_6 alkyl.

7. The compound according to any one of claims 1-6, wherein Ri is methyl.

8. The compound according to any one of claims 1-7, wherein R₂ is

9. The compound according to any one of claims 1-8, wherein Y is NR .

10. The compound according to any one of claims 1-9, wherein R4 is phenyl, optionally substituted by cyano, halogen, halogen -Ci_6 alkyl, or Ci_6 alkyl-0₂S-.

11. The compound according to any one of claims 1-9, wherein R4 is pyridinyl, optionally substituted by halogen or halogen-Ci-6 alkyl.

12. The compound according to any one of claims 1-11 selected from the group consisting of:

4-[4-(7-Methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)-piperazin-l-yl]- benzoic acid ethyl ester,

7-Methyl-2-(4^yridin-2-yl-piperazin-l-yl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one,

7-Methyl-2-[4-(3-trifluoromethyl^yridin-2-yl)-piperazin-l-yl]-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4 -one ,

2-[4-(3,5-Dichloro-phenyl)-piperazin-l-yl]-7-methyl-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4 -one , 7-Methyl-2-(4-pyrimidin-2-yl-piperazin -yl^

one,

2-[4-(7-Methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)-piperazin-l-yl]- nicotinonitrile, 4-(7-Methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)-3,4,5,6-tetrahydro-2H- [l,2']bipyrazinyl-3'-carbonitrile,and,

7-Methyl-2-(4-methyl-piperazin- 1 -yl)-3 ,7-dihydro-pyrrolo [2 ,3 -d]pyrimidin-4-one.

13. The compound according to any one of claims 1-11 selected from the group consisting of 7-Με^1-2^ο ^1ίη-4^1-3,7-ά^άΓθ-ρ}ττο1ο[2,3-ά]ρ}τ^ίάίη-4-οη6,

2-(4-Methanesulfonyl-piperazin-l-yl)-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4- one,

2-(4-Acetyl-piperazin-l-yl)-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one,

2- [3 -(4-Bromo-phenyl)-3 -methyl-azetidin- 1 -yl] -7 -methyl-3 ,7-dihydro-pyrrolo [2 ,3 - d]pyrimidin-4-one,

7-Methyl-2-(3-phenyl-pyrrolidin-l-yl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one,

2-[4-(3-Fluoro-phenyl)-piperazin-l-yl]-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4- one,

2-[4-(7-Methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)-piperazin-l-yl]- benzonitrile,

2-[4-(2,4-Difluoro-phenyl)-piperazin-l-yl]-7-methyl-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4 -one , 3-[4-(7-Methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)-piperazin-l-yl]- benzonitrile, and, 4-[4-(7-Methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)-piperazin-l-yl]- benzonitrile.

14. The compound according to any one of claims 1-11 selected from the group consisting of: 7-Methyl-2-[4-(2-trifluoromethyl-phenyl)-piperazin-l-yl]-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4 -one ,

7-Methyl-2-[4-(4-trifluoromethyl-pyridin-2-yl)-piperazin-l-yl]-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4-one,

2-[4-(3 ,4-Dichloro-phenyl)-piperazin- 1 -yl]-7-methyl-3 ,7-dihydro-pyrrolo [2 ,3 - d]pyrimidin-4 -one ,

7-But-3-enyl-2-[4-(2-chloro-phenyl)-piperazin-l-yl]-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4 -one , 2-[4-(2-Fluoro-phenyl)-piperazin-l-yl]-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4- one,

7-Methyl-2-(4-phenyl-piperazin-l-yl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one, 2-[4-(2-Chloro-phenyl)-piperazin-l-yl]-7-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4- one, 7-Methyl-2-(2,3,5,6-tetrahydro-[l,2']bipyrazinyl-4-yl)-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4 -one ,

6-[4-(7-Methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)-piperazin-l-yl]- nicotinonitrile,

2-[(lS,4S)-5-(3-Fluoro-phenyl)-2,5-diaza-bicyclo[2.2.1]hept-2-yl]-7-methyl-3,7-dihydro- pyrrolo[2,3-d]pyrimidin-4-one and

15. The compound according to any one of claims 1-11 selected from the group consisting of:

1- Ethyl-6-(4-trifiuoromethyl-phenyl)-l,5-dihydro-pyrrolo[3,2-c]pyridin-4-one and 1 -Methyl-6-(l -methyl- lH-pyrazol-4-yl)- 1 ,5 -dihydro-pyrrolo [3 ,2-c]pyridin-4-one .

16. The compound according to any one of claims 1-11 selected from the group consisting of

7-Ethyl-2-(4-trifiuoromethyl-phenyl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one,

7-Propyl-2-(4-trifluoromethyl-phenyl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one, 7-Allyl-2-(4^rifluoromethyl^henyl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one,

7-(2,3-Dihydroxy-propyl)-2-(4-trifluoromethyl-phenyl)-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4-one,

2-[4-(2-Fluoro-phenyl)-piperazin-l-yl]-7-hydroxymethyl-3,7-dihydro-pyrrolo[2,3- d]pyrimidin-4-one,

2-[4-(2,6-Difluoro-phenyl)-piperazin-l-yl]-7-(2,3-dihydroxy-propyl)-3,7-dihydro- pyrrolo [2 ,3 -d]pyrimidin-4-one , and,

7-Methyl-2-phenyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one.

17. The compound according to any one of claims 1-11 which compound is 2-[4-[2 6- difluoro-4-(2-methoxyethoxy)phenyl]piperazin-l -yl]-7-(2-hydroxyethyl)-3H-pyrrolo[2 3- d]pyrimidin-4-one.

18. A compound of formula I according to any of claims 1-17 for use as therapeutically active substance.

19. A method of inhibiting tankyrase 1 and/or tankyrase 2 by contacting either or both with a compound of any one of claims 1 to 17.

20. A method for treating cancer by administering to a patient in need thereof a therapeutically active amount of a compound according to any one of claims 1 to 17.

21. The method of claim 20 wherein the cancer is colorectal cancer.

22. The use of a compound according to any one of claims 1 to 17 for the preparation of a medicament for the treatment of cancer, in particular colorectal cancer.

23. A compound of formula (I) according to claims 1-17 for the use as therapeutically active substance for the therapeutic and/or prophylactic treatment of cancer, in particular colorectal cancer.

24. A composition containing a compound according to any one of claims 1 to 17 and at least one pharmaceutically acceptable carrier, diluent or excipient.

25. The invention as described hereinabove.

***